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Until 2001 chemotherapy and hormonal therapies were the mainstays of systemic treatment 
of solid tumors. In 2001 it was shown that activation of the mutated c-Kit receptor in gastrointes-
tinal stromal tumors (GIST) could be blocked by imatinib, a c-KIT tyrosine kinase inhibitor. This 
was one of the first successes of targeted therapy in solid tumors apart from the already long 
existing anti-hormonal therapy. The objective response rate in metastatic and unresectable GIST 
went from 0-5% for chemotherapy up to 38% for imatinib [1]. In recent years, more and more 
drugs specifically targeting diverse tumor characteristics have been developed. Unfortunately, 
not all targeted agents were as successful and in most cases, the effect of targeted agents is 
temporarily and often only seen in a subgroup of patients. 
A major challenge in oncology is to identify patients that will benefit from various targeted 
agents. Eventually, this should lead to ‘personalized medicine’: a specific drug to treat a specific 
tumor with specific molecular or genetic characteristics in a specifically selected patient. 
Molecular profiling of tumor tissue is important in this regard, but there may also be a role 
for molecular imaging in selecting patients and predicting tumor responses. The advantage 
of molecular imaging is that it is non-invasive and all tumor lesions can be assessed which 
addresses tumor heterogeneity and circumvents sampling errors. 
Another application of molecular imaging may be the (early) assessment of tumor responses. 
Treatment with targeted drugs may not always lead to a direct volume response of the tumor. 
Response assessments based on tumor diameter such as RECIST criteria for solid tumors on 
CT scans may therefore underestimate the anti-tumor activity of targeted agents [2]. In brain 
tumors, response assessment is especially difficult due to the blood brain barrier. Disruption or 
normalization of the blood brain barrier by the treatment complicates the evaluation of contrast 
enhanced MRI imaging [3]. Targeted drugs can block or reactivate pathways in tumors and 
modify the tumor microenvironment. This can potentially be visualized by molecular imaging 
with labeled drugs or labeled markers of pathway and microenvironment alterations. 
As anticancer treatments are becoming more effective, attention also needs to be paid to 
side effects of treatment and care for long term cancer survivors. Prognostic markers for toxicity 
due to anticancer treatments are therefore warranted. Early recognition of susceptibility for 
toxic effects of anticancer therapy can lead to early treatment adaptations and more specific 
follow up. 
The aim of this thesis is to provide novel insights in targeted drugs and the use of molecular 
imaging and biomarkers in anticancer treatments. 
outline of the thesis
Currently, the most frequently used way of systemic anticancer treatment is still DNA damage 
induction via chemotherapy. This DNA damage leads to apoptosis of tumor cells via the intrinsic 
apoptotic pathway. However, tumor cells often have mutations in this pathway, resulting in 
resistance to chemotherapy [4]. In addition, chemotherapy does not selectively affect tumor 
cells, but also induces damage to normal cells. Another way of inducing cell death is by targeting 
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the extrinsic pathway in tumor cells that induces apoptosis. One of the potentially interesting 
ways of doing this is via the TRAIL-R1 and TRAIL-R2 death receptors. Agonistic antibodies and 
recombinant TRAIL (rhTRAIL) can activate these receptors. In preclinical studies, it was found 
that these drugs can induce apoptosis and can enhance apoptosis in combination with chemo-
therapy and radiotherapy [5-7]. In chapter 2, a literature review was performed concerning the 
results of the phase 1 and 2 studies with the different agonistic antibodies against the TRAIL 
receptors and recombinant TRAIL. 
When the first studies with imatinib in GIST patients were conducted, a decrease of 
18F-fluorodeoxyglucose (FDG) uptake on PET scans was noted within days of starting imatinib 
therapy. It was suggested that this could be used as an early marker of therapeutic response 
in these patients [8]. Approximately 15% of GIST patients show primary resistance to imatinib, 
defined as progressive disease at first CT evaluation after 2 months [9]. In chapter 3 we retro-
spectively analyzed FDG-PET scans before start of imatinib and after 1 week of treatment 
initiation in 36 patients and compared the results with the outcome on CT scan after 2 months 
of treatment. We investigated whether early changes in tumor FDG uptake can predict primary 
imatinib resistance.
In brain tumors, the use of FDG-PET scans is hampered by the high uptake of glucose in 
normal brain tissue. However, accurate assessment of response to standard therapy with MRI 
imaging in glioblastomas is extremely difficult. Progressive lesions may not represent tumor 
growth, but rather a treatment effect that subsides in time without a change of therapy. This 
phenomenon is called pseudoprogression and seen in up to 64% of the patients with progres-
sive disease on MRI directly after radiotherapy [10]. The difficulty to distinguish recurrent tumor 
growth (true progression) from pseudoprogression complicates the clinical decision making in 
these patients: in case of pseudoprogression, standard treatment with adjuvant temozolomide 
should be continued, whereas in case of true tumor progression, other treatment modalities 
or palliative care would be more appropriate. 18F-fluorothymidine (FLT) is a PET tracer that is 
taken up by proliferating cells and therefore it may be possible to use FLT-PET scans to discrimi-
nate true progressive tumors from pseudoprogression as in the latter less proliferation would 
be expected. In chapter 4 we prospectively investigated the capability of FLT-PET scans in 
discriminating between pseudoprogression and true progression in patients with newly 
diagnosed glioblastoma treated with radiotherapy and temozolomide. In 30 patients, FLT-PET 
scans were performed before start and 4 weeks after completion of concomitant radiochemo-
therapy. MRI scans were performed at these two time points and after 3 cycles of adjuvant TMZ. 
Pseudoprogression was defined as progressive disease on MRI after radiochemotherapy, with 
stabilization or improvement of enhancing lesions after 3 cycles of adjuvant TMZ. Changes in 
FLT uptake were compared between patients with true progression and pseudoprogression. 
Another challenge in the management of malignant gliomas is the lack of effective standard 
therapy for recurrent disease, despite numerous studies with targeted agents and chemothera-
peutics conducted in recent years. One reason for this might be that the blood-brain barrier 




gliomas is TGF-β, since it was shown that TGF-β functions as a tumor promoter in advanced 
cancer and is involved in glioma development [11,12]. In chapter 5, we describe a clinical 
study in which patients with recurrent high grade gliomas were treated with fresolimumab, a 
monoclonal antibody against TGF-β. To investigate whether the antibody actually reached the 
tumor, patients underwent a PET scan with 89Zirconium labeled fresolimumab before start of 
treatment.  
Testicular cancer patients are mostly treated with a combination of bleomycin, etoposide 
and cisplatin (BEP) chemotherapy. The cure rate is very high in this patient group. But about 10% 
of the patients treated with BEP develop bleomycin induced pulmonary toxicity and in up to 3% 
of the patients this is fatal [13]. TGF-β is involved in many cellular physiological and patholog-
ical processes in the body including the immune response, wound healing and fibrosis [14]. In 
preclinical studies, TGF-β is implicated as an important factor in the development of bleomycin 
induced pulmonary toxicity [15]. An early marker that can predict which patients will develop 
this toxicity is not available. In chapter 6 we investigated the prevalence of abnormalities that 
were suspect for bleomycin-induced pulmonary changes on post chemotherapy restaging CT 
scans and whether TGF-β1 and GDF15 (a member of the TGF-β superfamily) and Hs-CRP levels 
in plasma can be used as biomarkers for the occurrence of these changes in testicular cancer 
patients treated with bleomycin containing combination chemotherapy. In chapter 7 the thesis 
is summarized and future perspectives are given. Chapter 8 provides a summary of the thesis 
in Dutch.
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The extrinsic apoptotic pathway can be activated by the endogenous ligand TRAIL (Tumor 
Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand) by binding to the death receptors 
TRAIL-R1 and TRAIL-R2 on the cell surface. This pathway is currently evaluated as an anticancer 
treatment strategy. Both recombinant human TRAIL and several agonistic antibodies against 
TRAIL-R1 and R2 have been studied in single agent and combination studies and proved to be 
safe and well tolerated. In this article, the clinical studies published to date will be reviewed. 
Also, future perspectives and biomarker studies for selecting patients that will benefit from 
these agents will be discussed.
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introduCtion
There are several different ways of inducing apoptosis in malignant cells as an anticancer 
treatment strategy. The most frequently exploited ways of treating tumors is to induce DNA 
damage via chemotherapy and/or radiotherapy, thereby activating the mitochondrial (intrinsic) 
apoptotic pathway. An important regulator of the intrinsic apoptotic pathway is the tumor 
suppressor p53, which can induce apoptosis in response to DNA damage inflicted by chemo-
therapy and radiation. However, p53 function in tumor cells is often lost, resulting in resistance 
to chemotherapy. In addition, chemotherapy does not selectively affect tumor cells, but also 
induces damage to normal cells.
Another way of inducing cell death is by stimulation of apoptosis via the extrinsic pathway. 
The extrinsic pathway is independent of p53 and can be activated by the endogenous ligand 
TRAIL (Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand), a transmembrane 
protein and a member of the TNF super family [1]. Physiologically, TRAIL is considered to have 
an anti-inflammatory effect and to play a role in autoimmunity and anti-tumor surveillance [2-4]. 
TRAIL can induce apoptosis in tumor cells by binding to the death receptors TRAIL-R1 (DR4) and 
TRAIL-R2 (DR5) on the cell surface. These death receptors are present in a broad range of both 
normal cells and tumor cells [5]. Interestingly, recombinant human (rh)TRAIL induces cell death 
only in tumor cells and not in normal cells [6]. What causes this difference is still not elucidated. 
When death receptors are activated by TRAIL, these receptors undergo homo-trimerization. 
This trimer forms the death-inducing signaling complex (DISC) together with the Fas-associated 
death-domain (FADD) and pro-caspases 8 and 10. The activated caspases then activate caspases 
3, 6 and 7, eventually resulting in apoptosis. Active caspase 8 also cleaves Bcl-2 interacting 
domain (Bid) into truncated Bid(tBid), which then triggers the intrinsic apoptotic pathway by 
activation of caspase 9 and finally caspase 3. Important cellular proteins that inhibit activation of 
the extrinsic apoptotic pathway are cFLIP, a competitor of caspase 8, and the inhibitor-of-apop-
tosis proteins (IAPs) that inhibit caspase activity [7]. In preclinical studies, not only rhTRAIL but 
also the agonistic antibodies against TRAIL-R1 and TRAIL-R2 induced apoptosis in various tumor 
cell lines, while normal cells were spared [6,8,9]. RhTRAIL and the TRAIL-R antibodies, also called 
PARAs (pro-apoptotic receptor agonists), in addition enhance the cytotoxic effect of “classic” 
chemotherapy, targeted therapies and radiotherapy [10-12]. This has led to several studies that 
are finalized or are ongoing with PARAs as single agent or combined with chemotherapeutic as 
well as targeted agents. In this review the results of these studies will be summarized and future 
perspectives and the possible use of biomarkers for selecting eligible patients will be discussed.
CliniCal studies
In recent years, several phase 1 and 2 single agent and combination studies have been 
conducted with recombinant human TRAIL (dulanermin, (Amgen/Genentech)) targeting both 
TRAIL-R1 and TRAIL-R2 and the agonistic monoclonal antibodies to either TRAIL-R1 (mapatu-
mumab (Human Genome Sciences)) or TRAIL-R2 (lexatumumab (Human Genome Sciences), 




(Novartis)). These trials are summarized in Table 1.
Mapatumumab, lexatumumab, conatumumab and drozitumab are fully human IgG1 
antibodies, whereas tigatuzumab is a humanized IgG1 antibody and LBY135 a chimeric (mouse/
human) IgG1 antibody. 
single agent studies
dulanermin
In a phase 1 study with dulanermin, 71 patients with advanced cancer received up to 30 mg/
kg/day intravenously (iv) for 5 days every 3 weeks. This regime was found to be safe and well 
tolerated. Two patients with chondrosarcoma achieved a partial tumor response, and were still 
on treatment after 2.7 and 4.3 years, respectively. Furthermore, in two other sarcoma patients, 
tumor necrosis was found during surgery after the first cycle of dulanermin therapy, which is 
possibly an indication of dulanermin induced cell death. The serum half life of dulanermin was 
found to be 0.5–1 h. No antibodies against dulanermin were detected [13].
Mapatumumab
In two phase 1 trials with mapatumumab up to 10 mg/kg iv every 2 weeks or up to 20 mg/
kg iv every 4 weeks, the best responses were stable disease in respectively 19 out of 49 and 12 
out of 41 patients with advanced solid tumors. The maximum tolerated doses were not reached 
[14,15].
In a phase 2 study, patients with colorectal cancer received mapatumumab 10 mg/kg after 
2 loading doses of 20 mg/kg iv every 14 days. In a phase 2 study in patients with non-small cell 
lung cancer (NSCLC), patients received mapatumumab 10 mg/kg every 21 days. In both studies, 
no objective responses were observed, but respectively 12 out of 38 and 9 out of 32 heavily 
pretreated patients achieved stable disease [16,17].
In a phase 1b/2 trial in 40 patients with non-Hodgkin’s lymphoma (NHL) treated with doses 
of 3 or 10 mg/kg mapatumumab iv every 21 days, 2 complete responses and 1 partial response 
were seen in patients with follicular lymphoma and 11 patients achieved stable disease [18].
No anti-mapatumumab antibodies were found in the phase 1 trials. The mean plasma half life 
value for mapatumumab was found to be 19, 22 and 26 days respectively [14,15,18].
agonistic trail-r2 antibodies
Lexatumumab was studied as a single agent in two phase 1 studies in patients with advanced 
solid tumors. The maximum tolerated dose was found to be 10 mg/kg and this dose could be 
administered every 2  weeks. Dose limiting toxicities, seen in five patients in these 2 studies, 
consisted of elevations of serum amylase, bilirubin and transaminases. One of these patients 
developed septicemia and acute renal failure and died 25 days after the lexatumumab adminis-
tration. Stable disease was achieved in respectively 12 out of 37 and 9 out of 27 patients, while 
one mixed response was seen in a patient with Hodgkin’s lymphoma. In this patient a lung lesion 
became smaller but other lesions increased in size [19,20]. A phase 1 study with lexatumumab 
19








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Translating TRAIL-receptor targeting agents to the clinic | 
has also been conducted in 24 pediatric patients with solid tumors. Doses up to 10 mg/kg every 
14 days were found to be safe in this population. Five patients achieved stable disease. In one 
patient stable disease was ongoing at 17 months [21].
Drozitumab was investigated at doses up to 20  mg/kg every 14  days and the maximum 
tolerated dose was not reached. Twenty out of 41 evaluable patients achieved stable disease. 
Minor responses were found in 3 patients with colorectal cancer, ovarian cancer and chondro-
sarcoma with respectively 28%, 23% and 20% reduction in measurable disease [22].
In a phase 1 study evaluating tigatuzumab in doses up to 8 mg/kg iv every week, 7 out of 17 
patients experienced stable disease as a best result, with 1 patient having stable disease for over 
2 years. The maximum tolerated dose was not reached [23].
Conatumumab was studied in doses up to 20  mg/kg every 2  weeks in 37 patients. The 
maximum tolerated dose was not reached. One partial response was seen in a patient with 
NSCLC, who was still on treatment after 4.2 years. One minor response (24% decrease in tumor 
size) was observed in a patient with colorectal carcinoma and 14 patients achieved stable 
disease [24]. In another phase 1 study, conatumumab was also well tolerated and 9 out of 18 
patients achieved stable disease [25].
LBY135 monotherapy was investigated in doses up to 20 mg/kg every 3 weeks in 32 patients 
with advanced solid tumors. A minor response in one patient and a decrease in tumor markers 
in two patients were seen. There were no dose limiting toxicities in patients receiving LBY135 
monotherapy [26].
Pharmacokinetic analyses of these antibodies against TRAIL-R2 showed that the serum 
half life of the antibodies is around 14 days for lexatumumab, 9–19 days for drozitumab and 
13–19 days for conatumumab. The plasma half life of tigatuzumab is 6–10 days and preliminary 
results show a half life value of 10 days for LBY135 [19,20,22-24,26]. In one patient, antibodies 
against lexatumumab were found before treatment, but this finding was not confirmed in 
later samples [19]. Antibodies against drozitumab were found in one patient, but because the 
baseline test of this patient was also positive, this did not seem to be related to treatment [22]. 
In the study with LBY135, immunogenicity was found in 25% of the patients, which seemed to 
affect exposure in five patients during later doses [26].
efficacy of Paras as single agents
Side-effects in single agent studies were generally mild, with the side-effects seen most 
frequently being fatigue and nausea. All investigated PARAs were considered safe and well 
tolerated and a maximum tolerated dose was only found for lexatumumab. From preclinical 
data there were concerns about a possible toxic effect of PARAs, especially on the liver [27]. 
However, in the clinical studies so far, this was not confirmed.
Most of the single agent studies had a phase 1 character and were performed in heavily 
pretreated patients and are therefore not ideal to judge anti-tumor activity. Tumor responses 
were observed in lymphomas treated with mapatumumab and three partial responses in solid 




responses with mapatumumab were achieved at 9 and 11 months, the partial responses with 
dulanermin at 2 and 8  months and the partial response with conatumumab at 8  months. 
Interestingly, further decrease in tumor size was seen in some of these patients after about 9 
and 11 months (mapatumumab) and 22 months (conatumumab) [13,18,24]. Although these are 
only individual cases, this indicates that response evaluation with RECIST criteria after the first 
months of treatment might be underestimating the therapeutic efficacy of PARAs. This under-
scores the relevance of waterfall plots over time.
The clear difference between the half life values of dulanermin and the agonistic antibodies 
indicates that dulanermin is only shortly available to bind to death receptors on tumor cells after 
administration while the antibodies are present for a long time. However, this short availability 
does not preclude tumor responses. The precise consequences of these differences in half life 
for trial design are still unknown.
Combination studies
Based on preclinical data there is a strong rationale to combine PARAs with chemotherapy, 
radiotherapy and other targeted therapies as PARAs enhance their effect [10-12]. These combi-
nations theoretically induce cell death by targeting both the extrinsic and the intrinsic apoptotic 
pathway. Activation of both the extrinsic and intrinsic apoptotic pathway is amplified by the 
combination of PARAs with chemotherapy. PARAs amplify signaling of the intrinsic apoptotic 
pathway via tBid, while chemotherapy augments activation of the extrinsic apoptotic pathway 
via, among others, TRAIL receptor upregulation at the cell surface and reduction of cellular cFLIP 
levels. Proteasome inhibition with bortezomib results in pleiotropic effects, but bortezomib 
treatment is found to induce TRAIL receptor surface expression, reduce FLIP expression, block 
IAP functionality and prevent proteasomal degradation of p53 and pro-apoptotic Bcl2 family 
members in cancer cells [28]. Inhibition of the NF-kappaB, Akt or MAPK prosurvival pathways 
using cetuximab, rituximab or sorafinib synergizes with PARAs targeting the apoptotic pathway. 
The mechanism of drug interaction can be at the DISC resulting in enhanced DISC formation or 
more downstream causing reduced expression of anti-apoptotic Bcl-2 family members and IAPs 
[29,30].
dulanermin
In a phase 1b study, dulanermin in doses up to 8 mg/kg iv for 5 days or up to 20 mg/kg iv for 
2 days every 3 weeks was studied in combination with paclitaxel, carboplatin and bevacizumab. 
Of the 24 patients with NSCLC included, 1 patient achieved a complete response, 13 a partial 
response and the median progression free survival was 7.2 months. A maximum tolerated dose 
was not reached. Combination of dulanermin with these drugs did not significantly affect phar-
macokinetics of dulanermin [31]. Results of a randomized phase 2 study with paclitaxel and 
carboplatin ± bevacizumab ± dulanermin (8 mg/kg iv for 5 days or 20 mg/kg iv for 2 days every 
3 weeks) in 213 chemo naïve NSCLC patients showed that this combination is well tolerated. 
However, this combination did not result in a better objective response rate or progression free 
survival [32].
25
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Dulanermin in doses up to 8  mg/kg iv for 5  days every 3  weeks was also combined with 
rituximab during 4 cycles in patients with low-grade NHL. There were 3 complete and 3 partial 
responses out of 12 patients treated [33]. The preliminary results of a randomized phase 2 study 
in patients with relapsed follicular NHL did not show a better objective response rate for this 
combination (61.5% versus 63.6%) [34].
Preliminary results in colorectal cancer patients show that dulanermin (up to 8 mg/kg iv for 
5 days every 3 weeks) combined with irinotecan and cetuximab or dulanermin (up to 9 mg/kg 
iv for 3 days every 2 weeks) with leucovorin, 5-fluorouracil and irinotecan (FOLFIRI) is safe [35].
Mapatumumab
Mapatumumab in doses up to 30 mg/kg iv every 3 weeks was studied in combination with 
gemcitabine and cisplatin and in doses up to 20 mg/kg iv with paclitaxel and carboplatin in 
phase 1 studies. The maximum tolerated dose was not reached in either study. Partial responses 
were observed in respectively 12 out of 49 and 5 out of 27 patients. Combination of mapatu-
mumab with chemotherapy regimens did not seem to influence the pharmacokinetics of any 
agent [36,37].
Preliminary results from a randomized phase 2 trial of mapatumumab combined with carbo-
platin and paclitaxel in 111 patients with NSCLC show that this combination does not lead to a 
better response rate or longer progression free survival [38].
In a phase 1b study, mapatumumab (up to 30 mg/kg every 3 weeks) was combined with 
sorafenib (400 mg BID) in patients with advanced hepatocellular carcinoma and chronic viral 
hepatitis. Among 19 patients, a partial response was seen in 2 patients and 4 patients achieved 
stable disease [39].
agonistic trail-r2 antibodies
In a phase 1b study, the combination of lexatumumab up to 10 mg/kg every 2 weeks with 
gemcitabine or FOLFIRI or lexatumumab every 3 weeks with pemetrexed or doxorubicin was 
studied in 41 patients. Preliminary results show 2 partial responses in colorectal cancer patients 
in the FOLFIRI arm and 1 partial response in a patient with small cell lung cancer in the doxoru-
bicin arm. Pharmacokinetics of lexatumumab or the chemotherapeutics were not influenced by 
each other [40].
A randomized phase 2 study in 124 patients was performed comparing drozitumab or 
placebo plus paclitaxel, carboplatin and bevacizumab in previously untreated patients with 
NSCLC. The objective response rate did not differ between the two arms (respectively 40% and 
42%), nor did the progression free survival [41].
A phase 2 study of drozitumab (10 mg/kg every 3 weeks, after a loading dose of 15 mg/kg) 
with rituximab in patients with NHL previously treated with rituximab, showed that this combi-
nation was well tolerated and 20 out of 40 patients achieved an objective response, consisting 
of 2 complete responses and 18 partial responses [42].
Two phase 1b studies in metastatic colorectal cancer patients were performed, in which 




or FOLFIRI ± bevacizumab. All combinations were found to be well tolerated [43, 44].
Conatumumab was studied in combination with several chemotherapy regimens and 
targeted therapies. In previously untreated patients with advanced NSCLC, the combination of 
conatumumab (up to 15  mg/kg every 3  weeks) with paclitaxel and carboplatin resulted in 1 
complete response and 3 partial responses among 10 evaluable patients. Pharmacokinetics of 
conatumumab seemed not to be affected by combined treatment with paclitaxel and carbo-
platin [45].
Combination of conatumumab (up to 10 mg/kg every 2 weeks) with modified FOLFOX6 and 
bevacizumab in 12 patients with previously untreated colorectal cancer and combination with 
gemcitabine in 13 previously untreated patients with metastatic pancreatic cancer resulted in 
partial responses in respectively 5 and 4 patients. Pharmacokinetics showed no differences with 
those found in single agent studies [46,47]. 
Conatumumab (10 mg/kg every 2 weeks) in combination with panitumumab in pretreated 
metastatic colorectal cancer patients appeared to be safe, but did not result in objective 
responses in either patients with wild-type KRAS tumor status or mutant KRAS tumor status. 
Stable disease was seen in 8 out of 19 patients with wild-type KRAS and 4 out of 25 patients with 
KRAS mutant status [48].
Conatumumab (up to 15  mg/kg iv every 3  weeks) was also combined with AMG 479 (an 
insulin-like growth factor receptor 1 antagonistic antibody) in a phase 1 study. Three out of 9 
patients achieved stable disease. Dose limiting toxicities were not observed and no interactions 
were seen between these agents [49].
In a randomized phase 2 study the combination of gemcitabine with conatumumab (10 mg/
kg every 2 weeks) or AMG 479 or placebo in 125 patients with previously untreated pancreatic 
cancer was studied and showed that these combinations are well tolerated. Although no 
objective response was seen in the conatumumab arm, stable disease rate, progression free 
survival and 6  month survival seem to be better in the conatumumab and AMG 479 arms 
compared to placebo [50].
In a phase 1/2 open-label and double blind study in patients with metastatic or unresect-
able soft tissue sarcomas, patients were given conatumumab (15 mg/kg every 3 weeks) with 
doxorubicin or placebo with doxorubicin. Although this combination was safe, the addition of 
conatumumab did not improve the progression free survival or the response rates [51].
In the phase 1 trial with LBY135, 24 patients received LBY135 in doses up to 20 mg/kg every 
3  weeks in combination with capecitabine (2 times daily, 2  weeks on, 1  week off). In these 
patients, 1 partial response was seen [26].
efficacy of Paras in combination studies
Data of 6 randomized phase 2 studies are available. The results indicate that only the combi-
nation of conatumumab and gemcitabine shows a trend toward a longer progression free 
survival and 6 month overall survival [50]. Addition of dulanermin to rituximab in NHL patients 
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does not seem to improve the objective response rate compared to rituximab alone, nor did the 
addition of conatumumab to doxorubicin in soft tissue sarcoma patients [34,51].
There were 3 randomized studies in patients with NSCLC. Combination of paclitaxel and carbo-
platin with mapatumumab does not seem to improve the objective response rate or progres-
sion free survival compared to chemotherapy alone. The same was the case for dulanermin and 
drozitumab with paclitaxel, carboplatin and bevacizumab [32,38, 41]. Therefore regretfully no 
benefit of the addition of dulanermin, mapatumumab or drozitumab could be shown in these 
randomized phase 2 studies.
However, we know that the combination of cetuximab or panitumumab with bevacizumab 
and chemotherapy in colorectal patients performed worse than one of the antibodies separately 
[52,53]. Therefore the addition of other antibodies to bevacizumab may hide its anti-tumor 
activity. The reason for this is still unraveled; however bevacizumab effects on tumor vasculari-
zation could be involved in this.
Interpretation of the preliminary results of the non-randomized phase 2 combination studies 
is hampered by the limited size of the studies. In earlier phase 1 combination studies, waterfall 
plots show anti-tumor effects of treatment with PARAs, although responses often do not meet 
the formal current RECIST criteria for partial response [31,36,37,54].
FuTuRe peRspeCTIves 
ongoing studies
In Table 2, the diverse ongoing studies with PARAs are shown. Of special interest are the 
studies that combine PARAs with other targeted therapies, since targeting the apoptosis route 
on multiple levels might lead to improved effectiveness.
Although PARAs also enhanced the cytotoxic effects of irradiation in preclinical settings, 
no clinical trials investigating the combination of these agents with radiotherapy have been 
conducted to date. A phase 1b/2 study combining mapatumumab, radiotherapy and cisplatin in 
patients with advanced cervical cancer (NCT01088347) and a phase 1/2 study combining cona-
tumumab with gemcitabine, capecitabine and radiation therapy in patients with pancreatic 
cancer (NCT01017822) have been initiated.
Another approach is direct injection of recombinant adenovirus that encodes for TRAIL in 
tumor tissue. In a phase 1 trial these injections were given in the prostate of patients with prostate 
cancer. Preliminary results of the first 3 patients show that the injection was well tolerated [55].
novel Paras
In recent years several novel PARAs with improved properties targeting TRAIL receptors have 
been developed. Fusion of an antibody derivative to TRAIL can result in antibody targeting-
dependent activation of TRAIL and other TNF family members that are in their soluble form 
biologically less active [56]. A number of TRAIL fusion proteins have been constructed, where 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































based on a single chain variable fragment (scFv). The scFv can be directed against cancer specific 
targets such as EGFR [57], against AML cells using anti-CD33 scFv and against acute leukemic 
T-cells using anti-CD7 scFv [58,59].
Another approach to raise more effective PARAs is the computational design of TRAIL variants 
that bind TRAIL-R1 or TRAIL-R2 with stronger affinity and preferably have reduced affinity to 
the decoy receptors compared with rhTRAIL [60,61]. A novel antibody based approach is a 
tetrameric nanobody agonist targeting TRAIL-R2, TAS266 (Novartis) [62].
Biomarkers
Another important subject of intense investigation is the search for biomarkers that 
can predict the tumor response to these new agents and could thus be used to personalize 
treatment.
It would be of major interest to know whether apoptosis induction via TRAIL-R1 or TRAIL-R2 is 
influenced by the expression of these receptors and cellular downstream proteins in the tumors. 
Just immunohistochemistry of these targets in the tumor tissue may not be enough, since no 
clear relation between receptor expression and outcome has been shown in clinical studies so 
far [16-19, 36,37]. Other potential biomarkers for apoptosis are also evaluated in clinical trials 
[63,64]
In the preclinical setting the rate of O-glycosylation of TRAIL-R1 and TRAIL-R2 appears to be 
predictive of the sensitivity of tumor cells to dulanermin and drozitumab. In dulanermin and 
drozitumab sensitive tumor cells higher expression of mRNA encoding enzymes involved in 
O-glycosylation was found [65,66]. These enzymes can be assessed using immunohistochem-
istry assays, which are now tested in clinical trials with PARAs [32, 67].
Antibodies that are (radio)labeled could possibly also be used as biomarkers [68-72]. 
Preliminary results of an imaging study with 111Indium labeled mapatumumab in patients show 
that mapatumumab is taken up in part of the tumor lesions [73]. An imaging trial with 111Indium 
labeled CS1008 (tigatuzumab) is currently ongoing (NCT01220999). These imaging techniques 
could potentially predict availability of the drug at the tumor site and guide future therapy.
ConClusion
Based on its property to induce apoptosis in tumor cells while sparing normal cells, PARAs 
are of interest to explore as a new cancer treatment modality. In clinical studies, the use of both 
rhTRAIL and antibodies against TRAIL-R1 and TRAIL-R2 appears to be safe and side effects are 
generally mild. Monotherapy with these agents resulted in some anti-tumor efficacy which 
could occur after a long treatment period.
Combination of PARAs with other treatments seems to be safe. Although no full phase 3 studies 
have been performed, all results until now show only modest effects. The maximum tolerated 
dose with these (combinations of ) drugs was mostly not reached. This uncertainty about dosing 
could partly be addressed by molecular imaging and labeling of the drugs involved. If there 
is a role for these drugs, it will be in the setting of a rational combination therapy. Ongoing 
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(randomized) combination studies, including combinations with other targeted therapies and 
radiotherapy, are awaited. Furthermore, novel PARAs with improved properties targeting TRAIL 
receptors and new biomarkers and imaging strategies that may help to select patients might 
lead to higher response rates in future trials.
aCknowledgeMents
Supported by Grants RUG 2005-3361 and RUG 2005-3365 of the Dutch Cancer Society and 





[1] Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and 
characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995 
Dec;3(6):673-82. 
[2] Rus V, Nguyen V, Puliaev R, Puliaeva I, Zernetkina V, Luzina I, et al. T cell TRAIL promotes murine 
lupus by sustaining effector CD4 th cell numbers and by inhibiting CD8 CTL activity. J Immunol. 
2007 Mar 15;178(6):3962-72. 
[3] Hoffmann O, Priller J, Prozorovski T, Schulze-Topphoff U, Baeva N, Lunemann JD, et al. 
TRAIL limits excessive host immune responses in bacterial meningitis. J Clin Invest. 2007 
Jul;117(7):2004-13. 
[4] Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility 
to chronic inflammation and tumorigenesis. J Clin Invest. 2008 Jan;118(1):111-23. 
[5] Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J, et al. 
Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem. 2004 
Jun;52(6):821-31. 
[6] Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor 
activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999 Jul;104(2):155-62. 
[7] Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG, et al. The clinical 
trail of TRAIL. Eur J Cancer. 2006 Sep;42(14):2233-40. 
[8] Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, et al. Isotype-
dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J 
Immunol. 2001 Apr 15;166(8):4891-8. 
[9] Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel 
anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med. 2001 
Aug;7(8):954-60. 
[10] Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K, et al. Cooperation of the agonistic DR5 
antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve 
survival. Clin Cancer Res. 2008 Dec 1;14(23):7733-40. 
[11] Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R. Mapatumumab and lexatumumab 
induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in 
combination with bortezomib. Mol Cancer Ther. 2009 Feb;8(2):292-302. 
[12] Marini P, Junginger D, Stickl S, Budach W, Niyazi M, Belka C. Combined treatment with lexa-
tumumab and irradiation leads to strongly increased long term tumour control under normoxic 
and hypoxic conditions. Radiat Oncol. 2009 Oct 27;4:49. 
33
Translating TRAIL-receptor targeting agents to the clinic | 
[13] Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O’Dwyer PJ, Gordon MS, et al. Phase I 
dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor 
agonist, in patients with advanced cancer. J Clin Oncol. 2010 Jun 10;28(17):2839-46. 
[14] Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, et al. Phase I pharma-
cokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody 
with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. 
J Clin Oncol. 2007 Apr 10;25(11):1390-5. 
[15] Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, et al. A phase 1 study of mapatumumab 
(fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. 
Clin Cancer Res. 2008 Jun 1;14(11):3450-5. 
[16] Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C, et al. Phase II trial 
of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates 
the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with 
refractory colorectal cancer. Br J Cancer. 2010 Feb 2;102(3):506-12. 
[17] Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, et al. Phase 2 study of mapatumumab, 
a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, 
in patients with advanced non-small cell lung cancer. Lung Cancer. 2008 Jul;61(1):82-90. 
[18] Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, et al. A phase 1b/2 trial of 
mapatumumab in patients with relapsed/refractory non-hodgkin‘s lymphoma. Br J Cancer. 2010 
Dec 7;103(12):1783-7. 
[19] Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al. Phase 1 and pharmacokinetic study 
of lexatumumab in patients with advanced cancers. Clin Cancer Res. 2007 Oct 15;13(20):6187-94. 
[20] Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, et al. Phase I and pharmacokinetic 
study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. 
Ann Oncol. 2010 Feb;21(2):376-81. 
[21] Merchant MS, Chou AJ, Price A, Geller JI, Tsokos M, Graham C, et al. Lexatumumab: Results of 
a phase I trial in pediatric patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts). 
2010 May 20;28(15_suppl):9500. 
[22] Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, et al. A phase I safety 
and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients 
with advanced malignancies. Clin Cancer Res. 2010 Feb 15;16(4):1256-63. 
[23] Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, et al. Phase I trial of weekly 
tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). 




[24] Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, et al. A first-in-human study 
of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 
1;16(23):5883-91. 
[25] Doi T, Murakami H, Ohtsu A, Fuse N, Yoshino T, Yamamoto N, et al. Phase 1 study of conatu-
mumab, a pro-apoptotic death receptor 5 agonist antibody, in japanese patients with advanced 
solid tumors. Cancer Chemother Pharmacol. 2010 Dec 16. 
[26] Sharma S, de Vries EG, Infante JR, Oldenhuis C, Chiang L, Bilic S, et al. Phase I trial of LBY135, a 
monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced 
solid tumors. J Clin Oncol (Meeting Abstracts). 2008 May 20;26(15_suppl):3538. 
[27] Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, et al. Apoptosis induced in normal 
human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000 
May;6(5):564-7. 
[28] Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signalling and 
modulation: Are we on the right TRAIL? Cancer Treat Rev. 2009 May;35(3):280-8. 
[29] Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, et al. Reduction of TRAIL-induced mcl-1 
and cIAP2 by c-myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. 
Cancer Cell. 2007 Jul;12(1):66-80. 
[30] Daniel D, Yang B, Lawrence DA, Totpal K, Balter I, Lee WP, et al. Cooperation of the proapop-
totic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-hodgkin 
lymphoma xenografts. Blood. 2007 Dec 1;110(12):4037-46. 
[31] Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, et al. Phase 1b study of dulanermin 
(recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevaci-
zumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 2010 
Mar 20;28(9):1527-33. 
[32} Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E, et al. Randomized phase II study 
of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-
small-cell lung cancer. J Clin Oncol. 2011 Nov 20;29(33):4442-51. 
[33] Fanale M, Burris H, Yee L, Lucas J, Dimick K, Goldwasser M, et al. Results of a phase 1B study 
of recombinant human APO2L/TRAIL with rituximab in patietns with relapsed low-grade NHL. 
Annals of Oncology. 2008 June;19(suppl 4):161. 
[34] Belada D, Mayer J, Czuczman MS, Flinn IW, Durbin-Johnson B, Bray GL. Phase II study of 
dulanermin plus rituximab in patients with relapsed follicular non-hodgkin’s lymphoma (NHL). 
J Clin Oncol (Meeting Abstracts). 2010 May 20;28(15_suppl):8104. 
35
Translating TRAIL-receptor targeting agents to the clinic | 
[35] Yee L, Burris HA, Kozloff M, Wainberg Z, Pao M, Skettino S, et al. Phase ib study of recom-
binant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal 
cancer (mCRC) patients (pts): Preliminary results. J Clin Oncol (Meeting Abstracts). 2009 May 
20;27(15S):4129. 
[36] Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, et al. Mapatumumab, a fully 
human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine 
and cisplatin: A phase I study. Clin Cancer Res. 2009 Sep 1;15(17):5584-90. 
[37] Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, et al. Mapatumumab, 
an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with 
advanced solid malignancies: Results of a phase I and pharmacokinetic study. J Clin Oncol. 2009 
Sep 10;27(26):4413-21. 
[38] Von Pawel J, Harvey JH, Spigel DR, Dediu M, Reck M,  Cebotaru CL, et al. A randomized phase 
II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carbo-
platin and paclitaxel in patients with advanced NSCLC. J Clin Oncol. 2010;28 suppl(7s). 
[39] Sun W, Nelson D, Alberts SR, Poordad F, Leong S, Teitelbaum UR, et al. Phase ib study of mapa-
tumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma 
(HCC) and chronic viral hepatitis. ASCO Meeting Abstracts. 2011 February 03;29(4_suppl):261. 
[40] Sikic BI, Wakelee HA, von Mehren M, Lewis N, Calvert AH, Plummer ER, et al. A phase ib study 
to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, 
in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. J Clin Oncol (Meeting 
Abstracts). 2007 June 20;25(18_suppl):14006. 
[41] Karapetis CS, Clingan PR, Leighl NB, Durbin-Johnson B, O’Neill V, Spigel DR. Phase II study 
of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer 
(NSCLC). J Clin Oncol (Meeting Abstracts). 2010 May 20;28(15_suppl):7535. 
[42] Wittebol S, Ferrant A, Wickham NW, Fehrenbacher L, Durbin-Johnson B, Bray GL. Phase II 
study of PRO95780 plus rituximab in patients with relapsed follicular non-hodgkin’s lymphoma 
(NHL). J Clin Oncol (Meeting Abstracts). 2010 May 20;28(15_suppl):e18511. 
[43] Rocha Lima CS, Baranda JC, Wallmark J, Choi Y, Royer-Joo S, Portera CC. Phase ib study 
of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with 
metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts. 2011 February 03;29(4_suppl):546. 
[44] Baron AD, O’Bryant CL, Choi Y, Ashkenazi A, Royer-Joo S, Portera CC. Phase ib study of 
drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI {+/-} bevaci-
zumab (BV) in previously treated patients (pts) with metastatic colorectal cancer (mCRC). ASCO 




[45] Paz-Ares L, Sanchez Torres JM, Diaz-Padilla I, Links M, Reguart N, Boyer M, et al. Safety 
and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with 
advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts). 2009 May 
20;27(15S):e19048. 
[46] Saltz L, Infante J, Schwartzberg L, Stephenson J, Rocha-Lima C, Galimi F, et al. Safety and 
efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line 
treatment of patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol (Meeting 
Abstracts). 2009 May 20;27(15S):4079. 
[47] Kindler HL, Garbo L, Stephenson J, Wiezorek J, Sabin T, Hsu M, et al. A phase ib study to 
evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients 
(pts) with metastatic pancreatic cancer (PC). J Clin Oncol (Meeting Abstracts). 2009 May 
20;27(15S):4501. 
[48] Peeters M, Infante P, Rougier P:L,J., Uronis HE, Stephenson J, Schwartzberg LS, et al. Phase Ib/
II trial of conatumumab and panitumumab (pmab) for the treatment (tx) of metastatic colorectal 
cancer (mCRC): Safety and efficacy. ASCO Gastrointestinal Cancers Symposium. 2010;abstract 
443. 
[49] Chawla SP, Tabernero J, Kindler HL, Chiorean EG, LoRusso P, Hsu M, et al. Phase I 
evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients 
(pts) with advanced, refractory solid tumors. J Clin Oncol (Meeting Abstracts). 2010 May 
20;28(15_suppl):3102. 
[50] Kindler HL, Richards DA, Stephenson J, Garbo LE, Rocha Lima CS, Safran H, et al. A placebo-
controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus 
gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol (Meeting 
Abstracts). 2010 May 20;28(15_suppl):4035. 
[51] Demetri GD, Le Cesne A, Chawla SP, Brodowicz T, Maki RG, Bach BA, et al. First-line treatment 
of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in 
combination with doxorubicin or doxorubicin alone: A phase I/II open-label and double-blind 
study. Eur J Cancer. 2012 Mar;48(4):547-63. 
[52] Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, beva-
cizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009 Feb 5;360(6):563-72. 
[53] Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase 
IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and 
bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009 February 10;27(5):672-80. 
[54] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009 
Jan;45(2):228-47. 
37
Translating TRAIL-receptor targeting agents to the clinic | 
[55] Griffith T, Konety B, Joudi F, Aubert H, Cohen M, Ratliff T, et al. Phase I study of Ad5-TRAIL 
in men with clinically organ confined prostate cancer. AACR Meeting Abstracts. 2007 April 
14;2007(1_Annual_Meeting):4870. 
[56] Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U, et al. Differential activation 
of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed 
activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene. 2001 Jul 5;20(30):4101-6. 
[57] Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF, et al. Simultaneous 
inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis 
induction by an scFv:STRAIL fusion protein with specificity for human EGFR. J Biol Chem. 2005 
Mar 18;280(11):10025-33. 
[58] ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, et al. A novel 
AML-selective TRAIL fusion protein that is superior to gemtuzumab ozogamicin in terms of in 
vitro selectivity, activity and stability. Leukemia. 2009 Aug;23(8):1389-97.
[59] Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH, et al. Target cell-
restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-
related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res. 
2005 Apr 15;65(8):3380-8. 
[60] van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, et al. Designed tumor 
necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via 
the DR5 receptor. Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8634-9. 
[61] Reis CR, van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M, et al. Rapid and 
efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL 
variants. Cell Death Dis. 2010 Oct 21;1:e83. 
[62] Huet H, Schuller A, Li J, Johnson J, Dombrecht B, Meerschaert K, Cromie K, Bilic S, Li S, Garner 
A, Nunes S, Chopra R, Clark K, Yao M, Fawell S, Stover D,  Sellers WR, Ettenberg S. TAS266, a 
novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor 
efficacy than conventional DR5-targeted approaches. AACR Meeting Abstracts. 2012;3853. 
[63] Pan Y, Xu R, Peach M, Huang CP, Branstetter D, Novotny W, et al. Evaluation of pharmacody-
namic biomarkers in a phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced 
tumours. Br J Cancer. 2011 Oct 27. 
[64] Zoog SJ, Ma CY, Kaplan-Lefko PJ, Hawkins JM, Moriguchi J, Zhou L, et al. Measurement 
of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling. 




[65] Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. Death-
receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/
TRAIL. Nat Med. 2007 Sep;13(9):1070-7. 
[66] Punnoose EA, Wagner K, Amler L, Ashkenazi A. Sensitivity to apomab, an agonistic DR5 
specific antibody, is correlated with expression of specific O-glycosyl transferases in tumor-cell 
lines of both epithelial and non epithelial origin. AACR Annual Meeting. 2009;abstract 687. 
[67] Stern HM, Padilla M, Wagner K, Amler L, Ashkenazi A. Development of immunohistochem-
istry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. Clin 
Cancer Res. 2010 Mar 1;16(5):1587-96. 
[68] Kim H, Chaudhuri TR, Buchsbaum DJ, Wang D, Zinn KR. High-resolution single-photon 
emission computed tomography and X-ray computed tomography imaging of tc-99m-labeled 
anti-DR5 antibody in breast tumor xenografts. Mol Cancer Ther. 2007 Mar;6(3):866-75. 
[69] Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R. Novel in vivo imaging 
shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor 
effects of receptor agonist antibodies. Mol Cancer Ther. 2006 Dec;5(12):2991-3000. 
[70] Zhou L, Dicker D, Wang W, El-Deiry WS. Prediction of pro-apoptotic anti-cancer therapeutic 
response by visualization of death receptors and specific markers of apoptosis. AACR Annual 
Meeting. 2009;abstract 4471. 
[71] Rossin R, Kohno T, Hagooly A, Sharp T, Gliniak B, Arroll T, et al. Characterization of 
64Cu-DOTA-conatumumab: A PET tracer for in vivo imaging of death receptor 5. J Nucl Med. 
2011 Jun;52(6):942-9. 
[72] Duiker E, Dijkers E, Heerspink HL, de Jong S, van der Zee A, Jager P, et al. Development 
of radioiodinated rhTRAIL and a radiolabelled agonistic TRAIL receptor antibody for clinical 
imaging studies. Br J Pharmacol. 2011 Oct 20. 
[73] Oldenhuis C, Dijkers EC, Duiker EW, Fox NL, Klein JL, Gietema JA, et al. Development of radi-
olabeled mapatumumab and imaging in solid tumor patients who are treated with gemcitabine, 
cisplatin, and mapatumumab. J Clin Oncol (Meeting Abstracts). 2009 May 20;27(15S):e14521. 
39
Translating TRAIL-receptor targeting agents to the clinic | 
2

S.F. Oosting 1, M.W. den Hollander 1, B. Rikhof 1, D.B. Rouw 2, J.R. de Jong 3, P.L. Jager 4, A.H. 
Brouwers 3, A.J.H. Suurmeijer 5, W.J. Sluiter 6, W.T.A. van der Graaf 7, E.G.E. de Vries 1, 
J.A. Gietema 1, A.K.L. Reyners 1
Departments of 1Medical Oncology, 2Radiology, 3Nuclear Medicine and Molecular Imaging, 
5Pathology, 6Endocrinology, University of Groningen, University Medical Centre Groningen, 
Groningen, The Netherlands. 4Department of Nuclear Medicine, Isala Clinics,  Zwolle, The 
Netherlands. 7Department of Medical Oncology, Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands.
Submitted 
Previously presented at the ASCO Annual Meeting 2011
18F-FDG-peT response no early 
predictive marker for primary 






Background: Approximately 15% of gastrointestinal stromal tumor (GIST) patients show 
primary resistance to imatinib, defined as progressive disease on CT after 8 weeks. We inves-
tigated whether early change in tumor 18F-fluorodeoxyglucose uptake on positron emission 
tomography (FDG-PET) predicts primary imatinib resistance.
Methods: 36 metastatic or locally advanced GIST patients underwent FDG-PET scans before 
and 1 week after start of imatinib. Relationship between FDG-PET response (EORTC criteria) and 
CT response after 2 months of treatment (RECIST 1.0 and Choi criteria) was investigated. FDG 
uptake was measured as Standardized Uptake Value (SUV). 
Results: Of the 30 patients evaluable with FDG-PET, 26 experienced a response and 4 had 
stable disease. Mean tumor SUVmax decreased from 7.4 (SD 3.8, range 2.2-18.4) to 3.0 (SD 
2.1, range 0.1-11.8) after 1 week imatinib (P < 0.001). FDG-PET response had a high positive 
predictive value for clinical benefit (response or stable disease) according to RECIST 1.0: 92% 
(95% CI 75-99%) and Choi: 95% (95% CI 76-100%). The false negative rate was respectively 11% 
(95% CI 2-30%) and 9% (95% CI 1-30%). 
Conclusion: While FDG-PET response has a high positive predictive value for clinical benefit 
of imatinib in GIST patients, it does not predict primary resistance. 
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introduCtion
Gastrointestinal stromal tumors (GIST) are mesenchymal tumors that arise in the gastroin-
testinal tract. They are characterized by expression of CD117; the KIT receptor. Approximately 
80% of all GISTs have a gain of function mutation in KIT resulting in constitutive activation and 
continuous downstream signaling. Furthermore, 5-10% of GISTs have an activating mutation 
in the gene encoding platelet derived growth factor receptor α (PDGFRA). Imatinib is an oral 
tyrosine kinase inhibitor that inhibits signaling of both KIT and PDGFRα. The majority of patients 
with unresectable or metastatic GIST benefits from treatment with imatinib [1]. However, ± 
15% of GIST patients have primary imatinib resistant disease, i.e. progressive disease within 3 
months after start of treatment [2]. Earlier or upfront identification of primary resistance would 
spare these patients the side effects of ineffective therapy and allow an earlier switch to alter-
native treatment. To date, no predictive biomarkers to guide treatment decisions are available. 
However, it is well appreciated that imatinib can induce a rapid and dramatic decrease in glucose 
uptake in GIST [3-6].
The objective of this study was to investigate whether metabolic response early after initiation 
of treatment can be used to predict primary resistance to imatinib in patients with locally 
advanced or metastatic GIST. In addition, we studied whether the metabolic response correlated 
with progression free survival (PFS) or specific receptor tyrosine kinase gene mutations.
Materials and Methods
Patients and study design
This is a retrospective analysis of consecutive patients with newly diagnosed locally advanced, 
metastatic or recurrent GIST, who started treatment with imatinib between February 2001 and 
October 2007 at the University Medical Centre Groningen (UMCG). Imatinib was administered 
orally at 400 to 800 mg per day. Fourteen patients were part of an earlier study [4]. 
fdg-Pet
FDG-PET scans at baseline and after 1 week imatinib treatment were standard care from 
February 2001 for patients with advanced GIST in the UMCG. As of October 2007, a different PET 
scan protocol was used. Therefore, this analysis is restricted to GIST patients who underwent PET 
scans before October 2007. PET scans were performed on a Siemens ECAT EXACT HR+ scanner 
in 2D mode. Patients fasted for 6 hours. Ninety min after injection of 5 MBq/kg 18F-FDG, a whole 
body scan was performed (7-8 bed positions from femur to crown, 8 min per bed position of 
which 3 min transmission time). The iterative reconstruction algorithm AW-OSEM 2D was used 
with 2 iterations, 8 subsets and a Gaussian filter of 10 mm.
For each patient, a maximum of 5 target lesions was used for tumor evaluation. Target lesions 
were defined as the 5 most intense FDG accumulating tumor lesions. The FDG uptake was 
measured by calculating the Standardized Uptake Value (SUV) as described earlier in regions of 
interest (ROI) placed over tumor lesions, with Siemens Leonardo software [7]. The maximum SUV 




pixel value (SUV70 and SUV40) for each target lesion was measured. For all target lesions in a 
patient the mean SUVmax, the mean SUV70 and the mean SUV40 was calculated for both scans. 
For classification of metabolic tumor response, the EORTC criteria for FDG-PET imaging were 
used [7]. Also the previously reported thresholds for the single lesion with the most intense 
uptake at baseline (25% reduction, 40% reduction, <2.5 and <3.4 for SUVmax on the second scan) 
were tested [8] and the definition of metabolic response used by Choi et al (decrease of mean 
SUVmax with ≥70% to less than 2.5) [9]. 
Ct scan
CT scans were performed at baseline, after 8 weeks and every 3 months thereafter. For 
response classification, Response Evaluation Criteria for Solid Tumors (RECIST) version 1.0 was 
used as well as the criteria described by Choi et al [9,10].
Mutation analysis
Mutation analysis of KIT exons 9, 11, 13 and 17 and PDGFRA exons 12, 14 and 18 was performed 
as described previously [11]. 
outcome parameters
Primary resistance is defined as progressive disease after 8 weeks of treatment according 
to RECIST1.0 or the Choi criteria. Positive predictive value, negative predictive value and false 
negative rate of FDG-PET for primary resistance were calculated with 95% confidence intervals (CI). 
Progression free survival (PFS) was defined as the time from imatinib initiation until disease 
progression or death, whichever occurred first. For PFS analysis, the occurrence of a new lesion, 
or an increase in size of pre-existing lesions (as defined by RECIST 1.0), or development of an 
intra-tumoral nodule and/or an increase in ‘solid’ tissue, in the background of a hypodense 
lesion were considered progressive disease according to the ESMO guidelines for GIST [12,13].
statistics
For comparison of the mean SUV at the first and second FDG-PET scan, the Wilcoxon signed 
rank test was used. PFS was estimated with the Kaplan-Meier method. Patients were censored at 
the date of surgery for complete surgical resection and at the date of last follow up for patients 
alive and progression free at the time of analysis. 
results
Patients
Thirty six patients with a mean age of 62 years (range 23 - 81) were included. Nine patients 
had locally advanced disease and 27 patients had metastatic or recurrent disease. For charac-
teristics see Table 1. Two patients started with imatinib 400 mg 2 times daily, the others with 
400 mg once daily. The median follow-up time was 35 months (range 4 - 87+). In patients who 
received imatinib with a non-curative intent, median PFS was 23 months (range 2 - 83+ months) 
and in this subgroup median overall survival was 32 months (range 4 - 87+ months). Twelve 
patients received subsequent systemic treatment upon disease progression.  
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             Table 1. Patient characteristics.

























Metastatic sites, N (%)
Liver
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           N: number of patients
           a No KIT or PDGFRA mutation 
fdg-Pet assessment
The baseline FDG-PET scan was performed at a median of 2 days (range 1 - 46) before start 
of treatment. Four patients had no FDG-avid lesions and therefore did not undergo a second 
FDG-PET scan. These four patients had normal blood glucose levels and were not on glucose 
lowering medication. The repeat scan was performed at median 8 days (range, 6-10) after start 
of imatinib. In two patients, a different FDG-PET imaging protocol was used for the baseline and 
repeat scan; these patients were therefore excluded from the analysis, resulting in 60 FDG-PET 
scans of 30 patients available for quantification of metabolic response. Tumor FDG-uptake 
decreased from baseline with a mean SUVmax of 7.4 (SD 3.8, range 2.2 - 18.4) to a mean SUVmax of 




Relative changes in mean SUVmax for individual patients ranged from +7.3% to -97.8% (Fig. 2B). 
Based on change of mean SUVmax, 26 patients experienced a metabolic response according to 
EORTC criteria and four patients had metabolic stable disease (hereafter called non-responders). 
None of the patients had metabolic progressive disease. Analysis of mean SUV40 and mean 
SUV70 revealed a similar pattern with 26 responders and four non-responders, although 
according to mean SUV70, one non-responder had metabolic progressive disease. 
Predictive value of metabolic response
One out of 30 patients had non-measurable disease on CT, therefore data of 29 patients were 
available for response classification according to RECIST. Two patients had progressive disease, 
i.e. primary imatinib resistance. In six patients Hounsfield Units could not be measured, therefore 
evaluation according to the Choi criteria could be applied in 23 patients (Table 2). Positive 
predictive value of a metabolic response (estimated with mean SUVmax) for clinical benefit from 
imatinib is 92% (95% CI 75 - 99%) for RECIST and 95% (95% CI 76 - 100%) for the Choi criteria. 
As none of the metabolic non-responders in our cohort had primary imatinib resistant disease, 
a negative predictive value could not be calculated. The false negative rate of FDG-PET for 
prediction of clinical benefit from imatinib was 11% (95% CI 2-30%) for RECIST and 9% (95% CI 
Figure 1. (left) Tumor FDG uptake (in mean SUV
max 
with standard deviation) in 30 GIST patients before 
start and after 1 week imatinib (IM) treatment.
Figure 2. (below) A. Absolute and B. relative changes 
in tumor FDG uptake (in mean SUV
max
) in individual 
patients (N = 30) in up to 5 tumor lesions between 
baseline PET scan and PET scan after 1 week imatinib 
(IM) treatment. Grey dotted lines shows thresholds 
for response (-25%) and progressive disease (+25%) 
according to EORTC criteria.
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1–30%) for the Choi criteria. Of the four patients with a negative baseline FDG-PET scan, three 
had clinical benefit (two partial responses and one stable disease) and one had progressive 
disease according to RECIST. Based on the Choi criteria two out of three derived benefit from 
imatinib (both partial responses) whereas the third patient had primary resistant disease. 
Table 2. FDG PET versus CT response.
CT scan
RECIST (N = 29) Choi (N = 23)
CR/PR/SDa PD CR/PR/SDb PD
FDG-PET scan
Responsec 24 2 20 1
No response 3 0 2 0
FDG-PET response after 1 week and CT response after 8 weeks of imatinib treatment.
N = number of patients, CR = complete response, PR = partial response, SD = stable disease, PD = 
progressive disease
a CR (N = 1), PR (N = 9), SD (N = 17)
b CR (N = 1), PR (N = 16), SD (N = 5)
c decrease in mean SUVmax ≥ 25% and no new lesions and no visible increase in extent of tumor 
FDG-uptake >20% in the longest dimension
For mean SUV70 identical predictive values for primary imatinib resistant disease as for 
mean SUVmax were obtained and mean SUV40 performed worse. There was no difference in 
PFS between metabolic responders, non-responders and patients with non FDG-avid lesions 
when using mean SUVmax according to the EORTC criteria (Fig. 3). This was also the case for mean 
SUV70, mean SUV40, for the definition of response used by Choi et al and for SUVmax of the 
single lesion with the most intensive uptake at baseline according to the thresholds described 
by Holdsworth et al [8,9]. 
Figure 3. PFS in patients with a metabolic tumor response (N = 26, black line), patients without metabolic 
response (N = 4, grey solid line) and in patients with non FDG-avid tumor lesions (N = 4, grey dashed line). No 




Mutation analysis and metabolic response
In 25 of 36 patients, sufficient tumor tissue was available for mutation analysis. A KIT exon 11 
mutation was present in 15 cases (60%), a KIT exon 9 mutation in five (20%), a PDGFRA exon 18 
mutation in three (12%), and no mutation was found in either KIT or PDGFRA in two patients (8%).
One patient with a KIT exon 9 mutation and two patients with a PDGFRA mutation showed 
no FDG uptake in tumor lesions at baseline. One patient with a KIT exon 11 and one patient with 
a KIT exon 9 mutation were not evaluable for metabolic response. Metabolic response for 20 
patients according to mutation is shown in Fig. 4.
Figure 4. Change in tumor FDG uptake (mean SUV
max
 with standard deviation) after 1 week imatinib treatment 
according to mutation type: KIT exon 11 (N = 14), KIT exon 9 (N = 3), PDGFRA (N = 1) and in wild type tumors 
(N = 2). IM = imatinib.
disCussion
The results of the current study show that early FDG-PET response cannot be used to identify 
primary imatinib resistant disease in patients with GIST. Absence of an early metabolic response 
does not indicate that patients do not benefit from imatinib.
Furthermore, patients with primary resistant disease can have a metabolic response. 
Although we found high positive predictive values of metabolic response for clinical benefit 
from imatinib (92% for RECIST and 95% for the Choi criteria) the upfront chance of response or 
stable disease is 85%, which falls within the 95% CI of the positive predictive value. Therefore, 
little if any predictive information on treatment outcome is added by early assessing metabolic 
response. 
Stroobants et al. performed FDG-PET scans at baseline and after 1 week of imatinib treatment 
in 17 GIST patients [6]. From their study a positive predictive value of 92%, a negative predictive 
value of 75% and a false negative rate of 8% for patients who derive clinical benefit from imatinib 
(response plus stable disease as best response according to RECIST) can be calculated, which 
is comparable with our results. Recently FDG-PET results of a study on neoadjuvant imatinib 
treatment in operable GIST patients were reported [14]. Looking at metabolic responders versus 
non-responders after 1 week of treatment, a positive predictive value of 100%, a negative 
predictive value of 14%, and a false negative rate of 16% can be calculated for clinical benefit 
from imatinib, again in line with our findings. A possible explanation for incidental incongruence 
between antitumor activity and glucose uptake is given by Tarn et al [15]. They demonstrated in 
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vitro that different intracellular signaling cascades are responsible for imatinib induced down-
regulation of Glut4 expression and imatinib induced apoptosis in GIST cells. However, no asso-
ciation between reduction in Glut4 expression and reduction in FDG uptake in tumors of GIST 
patients treated with imatinib in the neoadjuvant setting was found [14]. Previous studies in 
GIST patients showed that metabolic response correlated with PFS, time to progression or time 
to treatment failure (i.e. disease progression or death from any cause whichever occurs first) 
[4,6,8,9,16].
In Table 3, the current and previous studies are summarized. We did not find a correlation 
between metabolic response and PFS despite testing different SUV parameters and multiple 
cut off values for metabolic response. This may be due to the different definitions of metabolic 
response that are used. EORTC criteria are based on a few small studies in which no GIST patients 
were included. These criteria should therefore be regarded as consensus recommendations 
rather than evidence based guidelines [7]. Also, adherence to EORTC FDG-PET criteria does not 
guarantee similar analysis, as for example the number of lesions to be assessed per patient is not 
defined. Furthermore, a description of how disease progression is determined, is only provided 
by Choi et al and differs slightly from the ESMO recommendation that we used [9,13]. Finally, 
the small size of these studies and the different timing of FDG-PET scans will clearly affect the 
results. 
We found no FDG uptake in tumor lesions before start of treatment in four out of 36 patients. 
This corresponds with previous findings [6,16,17]. The numbers of patients are too small to draw 
conclusions on prognostic or predictive value of a negative baseline FDG- PET scan. 
We studied metabolic response in GIST patients starting first line treatment, according to 
mutation. Although small numbers prohibit conclusions, the FDG-PET results for the three 
patients with a PDGFRA exon 18 mutation were striking: two patients showed non FDG-avid 
lesions and the third patient is the only patient with an increase in FDG uptake after 1 week 
imatinib treatment. This suggests that in tumors with a PDGFRA exon 18 mutation, metabolic 
response to imatinib differs from KIT mutated tumors. Metabolic response was seen in 85% of 
patients with KIT exon 11 mutations (23/27) and in 50% (2/4) of patients without KIT or PDGFRA 
mutations after 1 week imatinib [14]. Fuster et al. performed FDG-PET scans in imatinib resistant 
GIST patients before and after initiation of doxorubicin while continuing imatinib [18]. In 15 
patients with mutation analysis available, they demonstrated lower baseline SUVmax in patients 
with wild type KIT tumors compared to non-wild type KIT tumors. However, in another second 
line study with sunitinib in imatinib resistant GIST patients, no correlation was found between 
KIT mutational status and metabolic activity or metabolic response in 22 patients [19].
Limitations of our study are the retrospective nature and the relative small size of the cohort. 
However, the data presented support the conclusion that early assessment of metabolic 
response with FDG-PET after 1 week of imatinib treatment in GIST patients is not helpful for 
go-no-go decisions. Primary imatinib resistance cannot be reliably identified with this technique. 
Therefore absence of progressive disease at 2 and 4 months according to RECIST 1.0 remains the 
most robust way to identify patients with a survival benefit from imatinib [20]. For second line 
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treatment with sunitinib also the absence of progressive disease according to RECIST 1.0 at 3 
months seems the best way to identify patients benefiting from this treatment [21].
This does not preclude an important role for FDG-PET imaging in staging GIST patients, as 
FDG-PET can reveal metastases that are missed on CT [4,16,22,23]. 
In conclusion, the results of our study suggest that repeat FDG-PET imaging early after 
initiation of imatinib in patients with GIST is not informative for clinical decision making with 
regard to continuation of imatinib. Imatinib is an extremely effective agent for this disease 
and should, in the advanced setting, be continued until convincing clinical and/or radiological 
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Chapter 4 
serial FLT-peT scanning does 
not discriminate between true 
and pseudoprogression in newly 
diagnosed glioblastoma patients 





Background: Response evaluation in glioblastoma (GBM) patients after first line radiotherapy 
and temozolomide (TMZ) is hampered by the occurrence of progressive, contrast-enhancing 
lesions on MRI not reflecting true tumor progression. 18F-fluorothymidine (FLT) is a Positron 
Emission Tomography (PET) tracer that is taken up by proliferating cells. The goal of this study 
was to prospectively assess the value of FLT-PET in discriminating between true and pseudopro-
gression in patients with primary GBM treated with chemoradiotherapy.  
Methods: FLT-PET and MRI scans were performed before start and 4 weeks after chemoradio-
therapy. MRI scans were also performed after 3 cycles of adjuvant TMZ. Pseudoprogression was 
defined as progressive disease on MRI after chemoradiotherapy, with stabilization or reduction 
of enhancing lesions after 3 cycles of adjuvant TMZ. Changes in maximum standard uptake 
value (SUVmax) and tumor-to-normal brain tissue (T/N) ratios were calculated for FLT uptake and 
presented as the mean of the SUVmax in case of multiple lesions. Ki67 staining in the primary 
tumor and overall survival were analyzed. 
Results: Thirty patients, (28 GBM, two gliosarcoma (WHO grade IV)), were included. Of 24 
patients evaluable for pseudoprogression, seven showed pseudoprogression and seven true 
progression. No difference was found in changes of SUVmax and T/N ratios or changes in these 
parameters between these patient groups. A lower baseline FLT uptake predicted longer overall 
survival, but baseline FLT uptake did not correlate with Ki67. 
Conclusions: FLT-PET scans do not discriminate between true progression and pseudopro-
gression in GBM patients. Baseline FLT uptake appears to predict overall survival (NTR3680).
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introduCtion 
Glioblastoma (GBM) is the most common and most aggressive type of primary brain tumors, 
accounting for more than 50% of all gliomas with an incidence of 3.19 per 100.000 in the United 
States [1]. After surgery, the addition of temozolomide (TMZ) to standard 60 Gy radiotherapy has 
improved 2-year survival from 11 to 27% and 5-year survival from 2 to 10%. This is currently the 
standard of care for newly diagnosed GBM [2]. However, response evaluation of this treatment 
in these patients is problematic. This is due to the difficulty of distinguishing recurrent tumor 
(true progression) from pseudoprogression. The latter is defined as the detection of progressive 
gadolinium-enhanced lesions on an MRI scan immediately after the end of concurrent chemo-
radiotherapy, where spontaneous improvement occurs without further treatment other than 
adjuvant TMZ [3,4]. This is the case in up to 64% of patients with progression on the first MRI scan 
after radiotherapy [5]. The difficulty of distinguishing true progression from pseudoprogression 
hampers clinical decision making in these patients. In case of pseudoprogression, standard 
treatment with adjuvant TMZ should be continued, whereas in case of true tumor progression, 
other treatment modalities – although scarce – or palliative care might be more appropriate. 
18F-fluorothymidine (FLT) is a Positron Emission Tomography (PET) tracer that is taken up by 
proliferating cells. It is phosphorylated in the cell by thymidine kinase 1, which is involved in 
DNA synthesis, and subsequently trapped. FLT uptake reflects thymidine kinase 1 activity, and 
can be used as a measure of cell proliferation. In several tumor types, FLT uptake corresponds 
with the Ki67 proliferation index and its change correlates with the response to therapy [6,7].  
In glioma patients, FLT uptake has been used for tumor grading and was correlated with Ki67 
[8,9]. Moreover, FLT-PET performed better in predicting survival and recurrence in glioma patients 
than FDG-PET and MRI [10,11]. However, no prospective studies have yet been conducted on 
the efficacy of FLT-PET to discriminate between pseudoprogression and true progression. An 
effective technique to make this discrimination is urgently needed to improve clinical decision 
making in these patients. Therefore, the aim of this prospective study in patients with newly 
diagnosed GBM was to determine whether FLT-PET scans, performed before and after chemora-
diotherapy, can discriminate between true progression and pseudoprogression as measured by 
MRI after 3 courses of adjuvant TMZ.  
Patients and Methods 
Patients and treatment
Patients with newly diagnosed GBM or gliosarcoma (WHO grade IV, hereafter referred to as 
GBM) who were eligible for standard treatment with radiotherapy and TMZ were prospectively 
included. After surgical resection or biopsy, patients were treated with radiotherapy consisting 
of 2 Gy irradiation 5 out of 7 days per week during 6 weeks, for a total dose of 60 Gy. Patients 
received concomitant TMZ orally in a dose of 75 mg/m2 daily for 6 weeks. After a treatment break 
of 4 weeks, patients received up to 6 cycles of adjuvant TMZ (150–200 mg/m2) for 5 days every 




were introduced based on the results of the FLT-PET scan. Overall survival was calculated from 
date of informed consent to date of death or last known date alive, censored at time of analysis 
(November 2013). All patients gave written informed consent to participate in the study. The 
protocol was approved by the local ethics committee and registered in the Dutch trial register 
(NTR3680).  
imaging
Patients underwent standard radiologic follow up with MRI (1.5T using T1, T2 and contrast 
enhanced 3D T1 Gradient echo sequences) directly after surgery (baseline), 10 weeks after 
start of treatment (4 weeks after completing chemoradiotherapy), 22 weeks after start of 
treatment (after the third cycle of adjuvant TMZ or earlier as clinically indicated) and thereafter 
every 3 months. MRI data for this study were assessed by an independent neuroradiologist 
and a radiologist in training using the Macdonald criteria for tumor response evaluation [12]. 
Pseudoprogression was defined as progressive disease on MRI scan at 10 weeks, with stabiliza-
tion or reduction of enhancing lesions on MRI at 22 weeks. True progression was defined as 
progressive disease on both the MRI at 10 weeks and the MRI at 22 weeks.
FLT-PET scans were performed after surgery, but before start of radiotherapy (baseline) 
and 10 weeks after start of treatment (4 weeks after completing chemoradiotherapy). FLT was 
synthesized as described by Been et al [13]. Patients were instructed to fast for a minimum of 
4 hours before tracer injection of 200 MBq FLT intravenously, injected 30 minutes before PET 
scanning. PET scans were made on either HR+ or mCT PET scanners (Siemens, Knoxville). The 
maximum Standard Uptake Value (SUVmax) was assessed by drawing a region of interest (ROI) 
around every lesion on a separate reconstruction according to the European Association of 
Nuclear Medicine Research Ltd [14]. In case of multiple lesions, the mean of the SUVmax of the 
different lesions was calculated. FLT-PET scans were fused with the most recent MRI to differ-
entiate actual tumor from post-surgery effects outside the cerebrum if needed. The SUVmean for 
normal brain tissue was assessed by drawing a ROI in the contralateral brain tissue. Tumor-to-
normal ratios (T/N ratio) were determined by dividing the SUVmax of the tumor by the SUVmean of 
the normal brain tissue. A PET response was defined as a 25% decrease of the SUVmax between 
the first and second FLT-PET scan. 
ki67 immunohistochemical staining
Deparaffinized GBM tissue from primary surgery was used to evaluate the proliferation 
fraction of tumor cells (4-μm-thick tissue slices). Antigen retrieval was performed using 10 
mM Tris/1 mM EDTA (pH 9), in a microwave at 700 W. Endogenous peroxidase and biotin were 
blocked using routine techniques. The slides were incubated with the primary antibody, Ki67 
(Clone MIB-1; Dako, Glostrup, Denmark) at room temperature for 1 hour, followed by application 
of the secondary antibody peroxidase-conjugated rabbit anti-mouse serum (Dako, Glostrup, 
Denmark), and the tertiary antibody peroxidase-conjugated goat anti-rabbit serum (Dako, 
Glostrup, Denmark), for 30 minutes each. The first antibody was diluted 1/100 in 1% bovine 
serum albumin (BSA)/phosphate buffered saline (PBS). The secondary and tertiary antibodies 
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were diluted 1/100 in 1% BSA/PBS with 1% AB serum. Color development was performed with 
3,3′-diaminobenzidine (Sigma, Zwijndrecht, the Netherlands) for 10 minutes. The slides were 
scanned for hot spots of proliferative activity. In one high power field (400x magnification) the 
fraction of Ki67-positive nuclei/total number of nuclei was evaluated.
statistics
Mann Whitney U tests were used to compare FLT uptake between patients with and without 
pseudoprogression. To discriminate between true progression and pseudoprogression, 
Receiver Operating Curves were used to find an optimal cutoff point for FLT uptake and changes 
in uptake. A Fisher’s exact test was used to analyze categorical data. A Kaplan-Meier curve with a 
log rank test was used to analyze survival. A Pearson correlation test was used to calculate corre-
lations between FLT uptake and proliferation index. A two-sided P-value of < .05 was considered 
significant. For the Fisher’s exact test, a one-sided P value was given. Statistics were calculated 
in IBM SPSS statistics 20. Graphs were made using GraphPad Prism version 5.00 for Windows. 
results 
Patients
In total, 28 patients with GBM and two with gliosarcoma (WHO grade IV) were included in 
this study between November 2009 and November 2012. For patient characteristics, see Table 1. 
All but one patient completed radiotherapy. Seven patients did not complete concomitant TMZ, 
and of the 27 patients who started adjuvant TMZ, 16 patients did not complete the adjuvant 
courses. The most frequent reasons for this were progressive disease and thrombocytopenia. 
One patient with a secondary GBM underwent a short schedule of concomitant radiotherapy 
(23 x 2 Gy) and TMZ. The median overall survival for all 30 patients was 14 months (range 1-36 
months). Five patients were not evaluable for pseudoprogression because of early death, 
salvage surgery or clinical deterioration that prevented further participation in the study. One 
patient was not analyzable for the pseudoprogression analysis as only a baseline MRI before 
tumor resection was available (Fig 1). 




    Table 1: Patient characteristics.
Characteristic No. of patients (n 
= 30)
Median Range








Type of intervention 
Biopsy  3
Surgical resection 27
Baseline FLT-PET scans were performed 5 days (median) before start of radiotherapy. Two 
patients had their baseline FLT-PET scan 2 and 4 days after start of radiotherapy for logistic 
reasons. Follow-up FLT-PET scans were made 27 days (median) after completion of radiotherapy. 
Three patients had their follow up FLT-PET scan 1 day after the start of adjuvant TMZ. Finally, for 
logistic reasons two patients had their FLT-PET scan 6 and 22 days, respectively, after the start 
of adjuvant TMZ. 
Pseudoprogression 
A total of 24 patients were evaluable for pseudoprogression analysis (Fig 1). Pseudoprogression 
was seen in seven patients, and true progression in seven other patients (Figures 2 and 3).Ten 
patients had either stable disease or a complete response on MRI after 10 weeks (Table 2). 
We found no difference in or change of SUVmax and T/N ratio on FLT-PET scans between 
patients with pseudoprogression and those with true progression. With 25% reduction of SUVmax 
as a cutoff value, only two of the patients with pseudoprogressivon were identified, while three 
patients with true progression also showed a decrease in SUVmax over 25% (sensitivity 29%, spec-
ificity 43%). We also used optimal cutoff points found by others for identifying recurrent tumor 
of a SUV ≥ 1.34 and T/N ratio of ≥ 4.94 applied to FLT-PET scan at 10 weeks [15,16]. This approach 
also did not predict all cases correctly. Using a T/N ratio of ≤ 2.95 on the FLT-PET scan at 10 
weeks, we identified four out of seven patients with true progression and zero patients with 
pseudoprogression (sensitivity 100%, specificity 57%, one sided P = .04). ROC curves showed no 
other reasonable cutoff point for any parameter to discriminate between pseudoprogression 
and true progression. 
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Figure 2. FLT-PET images at baseline (left) and 10 weeks (right) and MRI images at baseline (left), 10 weeks 
(middle) and 22 weeks (right) of a patient with pseudoprogression. SUV
max 
on baseline FLT-PET was 1.44, SUV
max
 
at 10 weeks 0.74.
Figure 3. FLT-PET images at baseline (left) and 10 weeks (right) and MRI images at baseline (left), 10 weeks 
(middle) and 22 weeks (right) of a patient with true progression. SUV
max 




























1 1.55 3.4 1.33 2.8 14.2 NE SD 30 29
2 NU ND NU ND ND SD SD 40 36*
3 NU ND 0.81 3.1 ND PD SD 35 32
4 1.73 5.6 1.58 6.3 8.7 PD SD 35 17
5 1.24 3.1 1.46 3.2 -17.7 SD PD 40 20
6 1.75 4.4 0.95 2.9 45.7 SD PD 30 31
7 1.59 7.6 1.34 8.4 15.7 PD NE 25 10
8 2.18 14.5 0.74 4.4 66.1 PD PD 50 19
9 2.43 6.2 1.14 2.5 53.1 SD SD 30 24
10 NU ND NU ND ND CR PD 10 14
11 NU ND NU ND ND CR CR 50 28
12 2.84 9.8 1.64 5.1 42.3 SD ND 30 4
13 NU ND 0.96 1.7 ND PD PD 25 9
14 1.23 3.0 1.14 3.5 7.3 PD SD 60 27*
15 1.90 5.3 1.61 4.0 15.3 PD SD 18 9
16 3.00 5.9 1.26 2.6 58.0 SD PD 19 10
17 5.02 9.0 ND ND ND ND ND 50 1
18 4.17 8.7 2.67 3.3 36.0 PD SD ND 9
19 1.10 2.0 1.00 1.9 9.1 SD SD 40 25*
20 1.38 3.9 1.68 2.8 -21.7 PD PD 30 11
21 1.59 5.9 0.85 2.3 46.5 PD PD 25 22*
22 0.65 2.0 0.68 2.7 -4.6 PD PD 20 14
23 0.35 1.5 NU ND ND CR CR 15 19
24 1.64 6.6 ND ND ND SD ND 20 9
25 1.61 6.0 1.33 3.9 17.4 PD SD 50 17*
26 2.85 16.8 0.93 5.5 67.4 SD PD 60 6
27 3.70 9.5 1.80 5.3 51.4 PD PD 50 5
28 1.44 7.6 0.74 4.1 48.6 PD SD 50 13*
29 2.93 8.1 2.23 5.9 23.9 PD PD 7 7
30 1.42 3.3 ND ND ND SD SD ND 10
Abbreviations: PD = Progressive Disease, SD = Stable Disease, ND = Not Done, NE = Non Evaluable, NU =  
No Uptake, CR = Complete Response. 
*Patients censored at date last known alive. 
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overall survival 
In all 30 patients, a baseline FLT-PET scan was available (Figure 1). In November 2013, 24 
patients had died and six were censored at the last known alive date. The median SUVmax for all 
patients on baseline FLT-PET was 1.59. For patients with a SUVmax ≤ 1.59, median overall survival 
was longer compared to patients with a SUVmax > 1.59 (20 vs 9 months P = .01) (Figure 4). 
Figure 4. Kaplan-Meier curve for patients with SUV
max
 on first FLT-PET scan ≤ 1.59 and > 1.59. Overall survival is 
higher for patients with SUV
max
 ≤ 1.59 (P = .01). 
Proliferation index
In the 28 patients with available surgical specimens for Ki67 staining, the mean SUVmax at 
baseline FLT-PET did not correlate with the Ki67 index of the tumor tissue before treatment. 
disCussion 
In this prospective trial we determined that serially measured FLT uptake in GBM patients 
did not discriminate between true progression and pseudoprogression. Uptake and changes in 
uptake was measured on FLT-PET scans before (at baseline) and after chemoradiotherapy. Low 
FLT uptake at baseline was predictive of longer survival, but FLT uptake did not correlate with 
the Ki-67 index of the primary tumor. 
Despite the urgent need to distinguish between true progression and pseudoprogression in 
GBM patients, until now only retrospective studies have been performed on patients who had 
a radiological suspicion of recurrent brain tumor at different time points and showed variable 
results. In one such study, FLT-PET had a low specificity for identifying recurrent tumor from 
benign lesions in 20 patients [17]. Three other studies were able to discriminate between true 
progression and radionecrosis in 15, 19 and 21 glioma patients, respectively, using FLT kinetic 
values and the tumor-to-normal ratio [15,16,18]. A possible explanation for our findings is that 
FLT uptake in high-grade gliomas reflects not only trapping of FLT in proliferating tumor cells, 
but also disruption of the blood-brain barrier. As a result, areas with true progression as well as 
with pseudoprogression would show increased uptake. 
To limit the burden of trial participation for the patients in this poor prognosis group, we did 




is easy to obtain, mostly used in clinical practice and has been proven to be robust. However, 
kinetic analysis might be of interest to distinguish between true FLT uptake due to proliferation 
and FLT leakage that results from disruption of the blood brain barrier. There are several studies 
that support this, although others showed a good correlation between FLT kinetic values and 
SUV [19-24]. Using kinetic analysis has several disadvantages in practice. It is a time-consuming 
procedure, as the uptake in time needs to be assessed, and it requires collecting multiple arterial 
blood samples, both of which make the procedure burdensome for patients. Several studies 
have suggested other parameters for quantification of FLT-PET, such as proliferative volume 
and parametric response maps [25,26]. Due to the small numbers of patients in the studies 
performed so far and the different approaches used for quantification, direct comparison of 
the results is difficult. Consequently, we are unable to draw more definitive conclusions about 
the usefulness of FLT-PET in glioma. However, the use of SUVmax could also have limitations. For 
instance, the heterogeneity of the FLT uptake is not taken into account by using SUVmax only. 
Another constraint of the present study is that the optimal time points for serial FLT-PET 
scanning before and during GBM treatment are difficult to choose. Because the aim of this 
study was to differentiate between true and pseudoprogression after chemoradiotherapy, we 
performed the baseline FLT-PET scan after surgery. Scanning before surgery would reveal tumor 
uptake, but most patients undergo a gross total resection of tumor tissue. However, scanning 
after surgery may have led to increased uptake of FLT due to increased blood flow and increased 
proliferation as part of the wound healing process. 
A surprising finding was that a T/N ratio ≤ 2.95 on the FLT-PET scan at 10 weeks identified 
patients with true progression only, as patients with true tumor progression would be expected 
to have a higher proliferation rate. Because of the small numbers of patients in this analysis, this 
result should be interpreted with caution; future studies are needed to confirm if this is indeed a 
clinically relevant finding. Currently, two trials are investigating FLT as an imaging biomarker of 
early treatment response (NCT01880008, NCT00813566). 
In earlier studies, correlations between FLT uptake in brain tumors and the Ki67 index were 
found [8-10]. However, in these studies FLT-PET scans were often performed before surgery, 
whereas in the current study post-surgery FLT-PET scans were made. This might explain the lack 
of correlation between FLT uptake and Ki67 index. 
In the current study, pseudoprogression and true progression were determined based on the 
MRI results at 22 weeks. This time point was chosen due to its clinical relevance. After 3 adjuvant 
TMZ courses, the diagnosis of true progression results in cessation of TMZ, thus avoiding further 
side-effects of TMZ and enabling a timely switch to second-line therapy or inclusion in clinical 
trials. However, the selection of this time point may have resulted in overestimation of the 
number of patients with pseudoprogression. Taal et al. defined a period with stable disease of 6 
months after radiotherapy for the diagnosis pseudoprogression [3]. Applying this criterion would 
have classified two patients with pseudoprogression as having true progression. However, this 
did not improve the performance of the FLT-PET scan in discriminating between true progres-
sion and pseudoprogression. On the other hand, clinical signs of pseudoprogression can take 
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longer than 3 months to resolve, so we might also have underestimated the number of patients 
with pseudoprogression [27]. 
Fortunately, since the start of this study, several new initiatives have been initiated. The 
RANO criteria for glioma response evaluation on MRI have been developed, and this reduces 
the number of patients found with pseudoprogression [28,29]. Also, other imaging modalities 
such as perfusion MRI and 11C-methionine-PET have shown interesting results, although large 
prospective studies comparing multiple imaging modalities are still lacking [30,31]. 
In conclusion, our prospective study suggests that FLT-PET scanning is not useful in for 
discriminating between pseudoprogression and true progression in GBM patients treated with 
radiochemotherapy. 
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Background: Transforming growth factor-β (TGF-β) signaling is involved in glioma devel-
opment. The monoclonal antibody fresolimumab (GC1008) can neutralize all mammalian 
isoforms of TGF-β and tumor uptake can be visualized and quantified with 89Zr-fresolimumab 
PET in mice. The aim of this study was to investigate the fresolimumab uptake in recurrent high 
grade gliomas using 89Zr-fresolimumab PET and to assess treatment outcome in patients with 
recurrent high grade glioma treated with fresolimumab. 
Methods: Patients with recurrent glioma were eligible. After intravenous administration of 37 
megabecquerel (MBq) (5 mg) 89Zr-fresolimumab, PET scans were acquired on day 2 and/or day 
4 after tracer injection. Thereafter, patients were treated with 5 mg/kg fresolimumab intrave-
nously every 3 weeks. 89Zr-fresolimumab tumor uptake was quantified as maximum standard-
ized uptake value (SUVmax). MRI scans for response evaluation were performed after 3 infusions 
or as clinically indicated. 
Results: Included were 12 recurrent high grade glioma patients: ten glioblastoma, one 
anaplastic oligodendroglioma and one anaplastic astrocytoma. All patients underwent an 
89Zr-fresolimumab PET scan 4 days after injection. In four patients an additional PET scan was 
performed on day 2 after injection. SUVmax on day 4 in tumor lesions was 4.6 (1.5 - 13.9) versus a 
median SUVmean of 0.3 (0.2 - 0.5) in normal brain tissue. All patients showed clinical and/or radio-
logical progression after 1-3 infusions fresolimumab. Median progression free survival was 61 
days (25-80) and median overall survival 106 days (37-417). 
Conclusion: 89Zr-fresolimumab penetrated recurrent high grade gliomas very well, however 
this did not result in clinical benefit.
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introduCtion 
High grade gliomas are rapidly progressive brain tumors that are divided into anaplastic 
gliomas and glioblastomas based upon their histopathologic features. The 5-year survival rates 
for anaplastic oligodendroglioma, anaplastic astrocytoma and glioblastoma (GBM) are 49%, 
25% and 5%, respectively [1]. Apart from surgery, the standard treatment of gliomas is currently 
based on tumor cell death induction by radiotherapy and chemotherapy. Given the modest 
treatment results novel strategies for the treatment of malignant glioma are needed.
Transforming growth factor-β (TGF-β) acts as a tumor promoter in advanced tumors where 
it induces proliferation and metastasis and suppresses the immune response [2]. TGF-β and its 
receptors are overexpressed in GBM and TGF-β signaling is involved in multiple steps of GBM 
development and invasion [3-5]. Plasma TGF-β levels are elevated in GBM patients and decrease 
after surgical tumor resection [6]. In addition, progression-free survival (PFS) and overall survival 
(OS) are decreased in glioma patients with high levels of phosphorylated SMAD2 (p-SMAD2), 
the substrate of TGF-β receptor I, compared with glioma patients with low levels of p-SMAD2 [7]. 
These features make TGF-β a promising target molecule for therapeutic approaches in recurrent 
glioma and therefore several TGF-β-inhibitors are under investigation in this setting [8]. 
Fresolimumab (GC1008) is a monoclonal antibody capable of neutralizing all mammalian 
isoforms of TGF-β (i.e., 1, 2, and 3) [9]. In a phase 1 study with fresolimumab in patients with 
melanoma and renal cell carcinoma, six patients achieved stable disease and one patient had a 
partial response [10]. In a phase 2 study in 13 mesothelioma patients stable disease was seen in 
three patients at 3 months [11]. 
Current standard of care and experimental treatment results in patients with recurrent high 
grade glioma are disappointing. It is often suggested that this is due to the impermeability 
of the blood brain barrier which may prevent drugs from reaching the tumor [12]. For thera-
peutic success in brain tumors, it is essential for a monoclonal antibody like fresolimumab to 
reach the target site in the brain. In tumor xenograft models, tumor uptake could be visualized 
and quantified with Zirconium-89 (89Zr) fresolimumab PET [13]. Therefore the aim of this study 
was to visualize and quantify fresolimumab uptake in recurrent high grade glioma using 
89Zr-fresolimumab PET. In addition, we evaluated the effect of treatment with fresolimumab in 
recurrent high grade glioma patients. 
Material and Methods
Patients 
Adult patients with recurrent glioma with one or more contrast enhancing lesions of at least 
20 mm on MRI were eligible. Main other inclusion criteria were: WHO performance score 0 - 2, 
adequate bone marrow, coagulation, kidney and liver function and negative tests for hepatitis 
B, C and HIV. Previous surgery, radiotherapy, chemotherapy or investigational agents should 
have been >4 weeks prior to inclusion (>6 weeks for nitrosourea, or monoclonal antibodies) and 




ascites or pleural effusions, active hypercoagulability states or use of anti-coagulants, hyper-
calcemia, pregnancy or nursing mothers, diagnosis with other malignancies (unless curatively 
treated), organ transplants, immunosuppressive therapy, active infection, autoimmune disease, 
and other significant uncontrolled medical illnesses.
This study has been approved by the local medical ethical committee and registered in a 
clinical trial register (Trial registration ID: NCT01472731). All patients gave written informed 
consent. A data safety monitoring board reviewed the progress and safety during the study. 
treatment 
Patients were treated with 5 mg/kg fresolimumab (provided by Genzyme (Sanofi-Aventis 
Oncology)) intravenously every 3 weeks until radiological or clinical progression or unaccep-
table toxicity. Fresolimumab was administered over 90 minutes for the first infusion, thereafter 
over 60 minutes and finally 30 minutes if no infusion related reactions occurred. Within 30 
minutes before infusion, patients received acetaminophen (500 mg) and clemastine (2 mg) as 
premedication. All adverse events were recorded and graded according to CTCAE version 4. PFS 
and OS were calculated from date of informed consent to date of disease progression on MRI, 
clinical progression or death. 
imaging
Conjugation and radio labeling of fresolimumab was performed under good manufacturing 
conditions (GMP) as previously described [13]. Before start of treatment with fresolimumab, 
patients were injected with 37 MBq (5 mg) 89Zr-fresolimumab. The radioactive dose of 37 MBq 
and the protein dose of 5 mg results in a specific activity of 7.4 MBq/mg. Thereafter, patients 
were observed for 2 hours for possible infusion related reactions. 
89Zr-fresolimumab PET scans were acquired on day 4 after injection. To assess the tumor 
accumulation of 89Zr-fresolimumab over time, an additional scan was acquired on day 2 after 
injection in some patients. Normal organ distribution of 89Zr-fresolimumab was assessed by 
whole body PET scans. The images were acquired using two PET camera systems (ECAT HR+, 
Siemens Medical Systems, Knoxville, TN; mCT Biograph, Siemens Medical Systems, Knoxville, 
TN). Acquisition time for the ECAT HR+ PET camera was 10 minutes per bed position on day 
2 after injection (of which 20% is transmission time). On day 4 after injection, imaging time 
was prolonged to 12 minutes per bed position to correct for decay time. For the mCT camera, 
imaging time was shorter (5 minutes per bed position). All scans were reviewed and analyzed 
by a nuclear medicine physician (AG) and an investigator (MdH). All attenuation-corrected PET 
images and MRI series (gadolinium enhanced T1, performed within 4 weeks before start of the 
study) were retrospectively fused by using a commercially available software program (esoft, 3D 
fusion, Siemens Medical Solutions) on a Siemens Workstation (Syngo MMWP, Siemens Medical 
Solutions) to identify tumor lesions. The two datasets were aligned based on mutual informa-
tion using the anatomical contours of the loaded datasets. Regions Of Interest (ROIs) were 
drawn around the tumor lesions on the PET scans (MdH). In normal organs ROIs were drawn 
in the same area of the organs for all patients. 89Zr-fresolimumab uptake was quantified using 
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AMIDE Medical Image Data Examiner software (Stanford University, Palo Alto, CA) version 0.9.2 
to calculate the standardized uptake value (SUV) [14]. The maximum SUV (SUVmax) of the tumor 
lesions and the mean SUV (SUVmean) of normal organs including blood (measured in the sinus 
confluens and iliac artery) was calculated.
Follow-up brain MRI scans (1.5T using T1, T2 and contrast enhanced 3D T1 Gradient echo 
sequences) were performed after every 3 treatment cycles (every 9 weeks) or as clinically 
indicated. MRI data for this study were assessed by a neuroradiologist (JCdG) using the 
Macdonald criteria for tumor response evaluation [15]. 
Plasma pharmacokinetics and biomarkers
Heparin plasma samples were collected from patients 1 hour after injection and at the time 
of PET scanning for 89Zr-fresolimumab pharmacokinetics. Plasma samples were counted in a 
gamma counter and the tracer concentration in plasma was calculated using a calibration graph. 
Before start of fresolimumab treatment, citrate plasma samples were collected. Blood 
samples were drawn without tourniquet when possible, immediately placed on ice and centri-
fuged at 2500 g for 30 minutes at 4 °C without brake. Plasma samples were stored at -70 °C. 
In these samples, total TGF-β1 was analyzed using a human TGF-β1 immunoassay (Quantikine, 
R&D Systems Minneapolis, MN). 
p-SMAD2 was analyzed as a read out of TGF-β signaling in archival paraffin embedded 
primary tumor tissue of all patients. Formalin fixed, paraffin embedded 3-µm tissue sections 
were mounted on microscope slides and dried overnight at 55°C. Tissue sections were dewaxed 
in xylene, and rehydrated in graded series of ethanol. Sections were subjected to microwave 
pretreatment with pH 6.0 citrate buffer for staining of p-SMAD2 (# 3101 Cell Signaling 
Technology, Inc. Danvers, MA). Subsequently sections were treated with 0.3% H2O2 for 30 
minutes, blocked for 1 hour with 2% BSA to reduce nonspecific antibody binding and were 
incubated with primary antibody. All antibody solutions were made in PBS with 1% BSA and 
0.1% TritonX-100. Incubation at 4°C overnight was followed by incubation with goat anti-rabbit 
antibody conjugated to peroxidase (DAKO, Heverlee, Belgium) and subsequently with rabbit 
anti-goat antibody conjugated to peroxidase (DAKO). Staining was visualized by 3,3’-diami-
nobenzidine and sections were counterstained with hematoxylin and mounted. As negative 
control, primary antibody was omitted and incubations were performed as described above.
statistical analysis
In the protocol 2 stopping rules were defined. The study would be terminated i) after inclusion 
of six patients if no 89Zr-fresolimumab uptake was seen on the PET scan; and ii) after inclusion 
of 12 patients if treatment with fresolimumab showed no clinical benefit. If clinical benefit was 
seen a maximum of 20 patients could be included. Statistical analyses were performed using 
the Pearson correlation test and the Mann-Whitney U test using IBM SPSS statistics 20. Data are 
presented as median with range unless stated otherwise. Two-sided P - values of 0.05 or less 







Twelve patients with recurrent high grade glioma (nine primary glioblastoma, one secondary 
glioblastoma (WHO Grade IV), one secondary anaplastic oligodendroglioma and one secondary 
anaplastic astrocytoma (WHO grade III) were enrolled in this study (Table 1). Patients were 
previously treated with 2 lines of treatment (1 – 8). 
                    Table 1: Patient characteristics. 
Characteristic no


















No of previous treatments
Median (range) 2 (1-8)
Previous treatment
Surgery















Two patients received 1 infusion of fresolimumab, five patients received 2 infusions and five 
patients received 3 infusions. All patients showed clinical progressive disease during treatment 
or progressive disease on the first on-treatment MRI scan. PFS was 61 days (25 - 80) and OS 106 
days (37 - 417). In the absence of clinical benefit the study was closed after the first 12 patients. 
There were no adverse events related to tracer injection. In 12 patients 69 non hemato-
logic adverse events, mostly grade 1 or 2 and mostly related to progression of disease, were 
observed during the study. Thirteen hematologic grade 1 adverse events were registered. 
The most common adverse events were neurologic deterioration, headache, skin disorders, 
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nausea and fatigue (Table 2). Adverse events that were considered as possibly related to fresoli-
mumab were acneiform rash (grade 1, 1 patient), dry skin (grade 1, 1 patient), fatigue (grade 2, 2 
patients), thrombocytopenia (grade 1, 1 patient) and epistaxis (grade 1, 1 patient). Four serious 
adverse events were recorded, of which 3 were neurologic worsening related to progressive 
disease and one was pain related to an osteoporotic vertebra fracture, all assessed unrelated to 
fresolimumab.
Table 2: Hematologic adverse events and most common non hematologic adverse events. 
adverse event no of cases grade 1 grade 2 grade 3
Neurologic deterioration 16 3 8 5
Headache 12 7 3 2
Skin disorders 8 7 1
Nausea 7 3 3 1




In four patients no post treatment MRI was made because of clinical deterioration. In two 
patients, suspected dispersed hemorrhagic spots were seen in the tumor on post treatment 
MRI. A relationship with fresolimumab could not be excluded, although one of these patients 
also had a second course of radiotherapy prior to study entry. 
imaging 
All 12 patients underwent at least a “brain only” PET scan on day 4 after injection. Seven 
patients underwent a whole body scan. Four patients underwent a whole body scan on both 
day 2 and day 4 after injection. The interval between date of consent en injection of PET tracer 
was 7 days (0 - 15). 
In all patients uptake of 89Zr-fresolimumab was seen in tumor lesions (n = 16). The SUVmax in 
tumor lesions on day 4 was 4.6 (1.5 - 13.9), which was higher than the SUVmean of normal brain 
tissue (0.3 (0.2 - 0.5)) (P < 0.01). The SUVmean was 3.0 (2.0 - 6.2) in the blood of the sinus confluens. 
In patients with a whole body scan the SUVmean of normal organs was the highest in the heart (8.3 
(6.4 - 8.9)) followed by the liver (7.1 (5.4 - 11.2)) and the kidneys (5.5 (3.4 - 6.6)) (Figure 1). In eight 
patients, uptake of 89Zr-fresolimumab was not seen in each tumor lesion. Most tumor lesions 
that did not show uptake were small (< 10 mm on MRI). In three patients no uptake was seen in 
larger gadolinium enhanced lesions of 13, 18, and 12 mm respectively. The latter 2 lesions were 
found in previously irradiated areas and 1 of these was not visible on the follow up MRI scan 
(Figure 2). In all four patients who underwent a PET scan on both day 2 and day 4 after injection, 
the tumor to blood ratio (measured in the sinus confluens) increased from day 2 to day 4 after 




Plasma pharmacokinetics and biomarkers
The plasma concentration of 89Zr-fresolimumab at 1 hour, 2 days and 4 days after injection 
was 1.87 (1.20 - 2.30), 1.31 (0.96 - 1.76) and 1.06 (0.72 - 1.38) μg/mL respectively. When corrected 
for the injected dose, the extrapolated Cmax/dose was 0.37 (0.23 - 0.41) μg/mL/mg (n = 10). 
Pre-treatment plasma TGFβ1 levels were 2058 pg/mL (837 - 3444) and correlated with mean 
SUVmax in the tumor lesions 4 days post injection (r = 0.61, P = 0.04, (Figure 3)). p-SMAD2 staining 
in primary tumor tissue was positive for all tumors, but also for normal brain tissue (Figure 4). 
disCussion
This is the first study that shows tumor uptake of a radiolabeled antibody in recurrent high 
grade glioma patients, indicating that fresolimumab does reach its target destination within the 
brain. Unfortunately, mono-therapy with fresolimumab did not result in an antitumor effect. 
The median SUVmax of 4.6 found in the gliomas is comparable to the SUVmax of 5.8 (1.7 - 15.1) 
found in metastatic lesions with 89Zr-bevacizumab PET in patients with neuroendocrine tumors 
[16]. The Cmax/dose of 
89Zr-fresolimumab 1 hour after injection of 0.37μg/mL/mg is comparable 
to the pharmacokinetic results of an earlier study with fresolimumab [17]. This indicates that 
the radio labeled antibody has a similar Cmax with fresolimumab compared to other studies. 
Three contrast enhancing lesions >10 mm did not take up 89Zr-fresolimumab. Two were found 
in previously irradiated areas and one of these disappeared on follow up MRI. These lesions 
are suspected to represent radionecrosis instead of viable tumor tissue which might be the 
reason for the lack of TGF-β and uptake of 89Zr-fresolimumab. In all patients who underwent 
a whole body PET scan on both day 2 and day 4 after injection, the tumor to blood ratio 
increased. This increase in ratio supports tumor specific uptake. This pattern of tumor accumula-
tion and increasing tumor to blood ratios over time was also seen in our preclinical study with 
Figure 1. A: Representative example of 89Zr-fresolimumab PET on day 4 and uptake in the brain tumor (arrow). 
B: Uptake of 89Zr-fresolimumab in different organs (SUV
mean
) and tumor (SUV
max
) on day 4 after tracer injection. 
Blood pool uptake was measured in the sinus confluens. Blood, brain and tumor values measured in n = 12, other 
organs in n = 7 patients. 
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Figure 2. A: Fused MRI and PET scan of a patient with 2 contrast enhancing lesions. High uptake visible in 
the frontal lesion (left image). No uptake visible on PET scan in occipital lesion (right image, arrow) that was 
previously irradiated. B: MRI and fused MRI/PET images of a patient with 2 contrast enhancing lesions. The 
SUV
max
 in the progressive right frontal lesion was 5.5. The SUV
max 
in the previously irradiated lesion paraventricular 
right was 2.1. C: Whole body PET scan on day 2 (left) and day 4 (right) with increase of SUV
max
 in frontal brain 
lesion (black arrows) from 4.0 to 5.5. Tumor to blood ratio increased from 0.8 to 1.2. D: Tumor to blood ratios on 
89Zr-fresolimumab PET in 4 patients on day 2 and day 4 after injection. 
Figure 3. (left) Correlation between TGFβ1 in plasma and 
mean SUV
max 
of 89Zr-fresilimumab in brain tumor lesions on 
day 4 after injection (r = 0.61, P = 0.04).
Figure 4. (below) A: H&E staining of GBM with central 




89Zr-fresolimumab and in brain metastases in a clinical study with 89Zr-trastuzumab in metastatic 
breast cancer patients [13,18]. Taken together these findings suggest that 89Zr-fresolimumab 
uptake was not only a reflection of antibody leakage due to a damaged blood brain barrier but 
was tumor specific and TGF-β driven. 
In earlier studies the uptake of gemcitabine and GRN1005 in recurrent glioma patients was 
shown by analyzing tumor tissue obtained during surgery [19,20]. However, performing tumor 
biopsies is often not feasible in this patient group and tumor characteristics may change over 
time. PET scanning can be a non-invasive alternative for exploring potential drugable targets 
and showing tumor penetration of drugs. 
Treatment with fresolimumab was generally well tolerated, without infusion related reactions. 
Most adverse events were grade 1 or 2 and related to progression of disease. Unfortunately, no 
clinical benefit was observed in this small and often extensively pretreated patient group in 
which only one dose of fresolimumab was tested. Possible effects of this treatment in higher 
doses can therefore not be excluded. The median PFS was 61 days, which is comparable to the 
PFS of physician choice chemotherapy arm in recurrent glioblastoma in a recently conducted 
randomized phase 3 trial [21].
In all archival tumor samples, p-SMAD2 was positive, indicating that the TGF-β pathway was 
active in the tumors. In gliomas multiple signaling pathways are activated, and inhibition of 
just one pathway might be insufficient for a response [22]. Recently, other clinical studies using 
TGF-β inhibition in glioma patients have been published. Traberdersen is an antisense oligode-
oxynucleotide that inhibits TGF-β2. In a randomized 2b study traberdersen was administered 
intra-tumorally by convection-enhanced delivery and compared with standard chemotherapy 
in patients with recurrent/refractory high-grade glioma. Six-month tumor control rates were 
not significantly different in the entire study population (anaplastic astrocytoma and GBM). 
Pre-specified anaplastic astrocytoma subgroup analysis showed a significant benefit regarding 
the 14-month tumor control rate for trabedersen vs chemotherapy [23]. A phase 1 study with 
LY2157299 (a TGF-β receptor 1 kinase inhibitor) showed confirmed responses in treatment 
refractory gliomas in three out of 28 patients [24]. TGF-β therefore remains a potential inter-
esting target in glioma patients, and more (combination) studies are welcomed. 
ConClusion
In this study it was proven that an antibody against TGF-β reaches recurrent high grade 
gliomas. Although no treatment benefit was seen, this finding could be exploited for further 
development of recurrent high grade glioma treatment with antibodies or antibody-drug 
conjugates. 
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Bleomycin-induced pulmonary 
changes on restaging CT scans 
in two thirds of testicular cancer 





Background: Metastatic testicular cancer has a favorable prognosis when treated with BEP 
(Bleomycin, Etoposide and cisPlatin) chemotherapy. Bleomycin-induced pneumonitis (BIP) 
is a well known side-effect which can be fatal. In this study, we investigated the prevalence 
of lesions suspect for bleomycin-induced pulmonary changes on restaging CT scans after 
treatment, and whether the fibrosis markers Transforming Growth Factor-beta1 (TGF-β1), 
Growth Differentiation Factor-15 (GDF-15), and hs-CRP were predictive of this.
Methods: Patients between 18 and 50 years of age with metastatic testicular cancer treated 
with BEP chemotherapy were included in this prospective non-randomized cohort study. 
Post chemotherapy restaging CT scans were analyzed for abnormalities that were suspect for 
bleomycin-induced pulmonary changes as judged by two independent radiologists. The radio-
graphic abnormalities were graded as minor, moderate or severe. Plasma samples were collected 
before, during and after treatment and were quantified for TGF-β1, GDF-15 and hs-CRP. 
Results: 66 patients treated with BEP chemotherapy were included. Forty-five (68%) showed 
signs of bleomycin-induced pulmonary changes on the restaging CT scan, 37 were classified 
to have minor and eight to have moderate abnormalities. No differences in TGF-β1, GDF-15, or 
hs-CRP plasma levels were found between these groups. 
Conclusion: Bleomycin-induced pulmonary changes are very common on restaging CT scans 
after BEP chemotherapy for metastatic testicular cancer. TGF-β1, GDF15 and hs-CRP plasma 
levels before, during and after treatment are not different between patients with and without 
radiological signs of pulmonary bleomycin-induced toxicity and, therefore, not helpful as early 
fibrosis biomarkers to predict this. 
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introduCtion  
Metastatic testicular cancer has a favorable prognosis with a 5 year overall survival over 90% 
when treated with the current standard of BEP (bleomycin, etoposide and cisplatin) chemo-
therapy. Bleomycin is considered to be an essential component of the regimen [1]. Although 
well tolerated, in roughly 10% of the patients treated with this regime, bleomycin-induced 
pulmonary toxicity (BIP) is observed, with clinical symptoms such as dry cough, dyspnea, 
crackles during auscultation, abnormalities on chest X-ray and fever [2]. BIP is predominantly a 
fibrotic lung disease and, although its pathogenesis is not resolved, the immune system appears 
to be involved [3,4]. 
BIP occurs during bleomycin treatment, but can also develop after a treatment free interval 
of weeks to months [5]. In 1-3% of the affected patients pulmonary toxicity is fatal [6]. The 
cumulative bleomycin dose is an important denominator of the risk of BIP, although a safe dose 
has not been established [7]. Known risk factors are smoking, impaired renal function and higher 
age, but there is neither a test to predict which patients will develop BIP, nor a therapy to prevent 
it [8,9]. Standard strategy in case of BIP signs during treatment is to stop bleomycin administra-
tion. The change in diffusion capacity (TLCO) is used in several centers to terminate bleomycin 
administration, although these changes appear not to be specifically caused by bleomycin [10]. 
In earlier reports, restaging CT scans after completion of BEP chemotherapy for testicular 
cancer are reported to show signs suggestive for bleomycin-induced pulmonary changes 
[11-13]. These radiologic changes may be a good surrogate endpoint for the susceptibility for BIP. 
However, since the bleomycin effect on CT scan is observed only after completion of treatment, 
an upfront or early biomarker that identifies patients likely to develop BIP would be preferable as 
these patients could be treated with a non bleomycin containing schedule. An early biomarker 
change would facilitate a premature halt of the weekly bleomycin administration. 
Transforming growth factor-beta 1 (TGF-β1) is a cytokine involved in many physiological and 
pathological processes, including immune response, cell proliferation, angiogenesis, fibrosis 
and oncogenesis [14]. TGF-β1 plays an important role in development of BIP and fibrosis in 
animal models [15-17]. In patients treated with radiotherapy, or patients that underwent stem 
cell transplantation, a relationship between TGF-β1 levels and treatment-induced pulmonary 
toxicity was found [18-19]. Growth differentiation factor 15 (GDF-15) (also known as macrophage 
inhibitory cytokine 1 (MIC-1)) is a member of the TGF-β1 super family. GDF-15 levels are upreg-
ulated in many cancer types [20]. GDF-15 expression is induced during fibrosis development 
and correlates with lung function impairment in systemic sclerosis patients [21]. GDF-15 is a 
product of activated macrophages and hereby a role player in inflammatory processes [22]. In 
addition, we evaluated the role of the known inflammation marker high sensitive C-reactive 
protein (hs-CRP).
In this study, we investigated the prevalence of lesions suspect for bleomycin-induced 
pulmonary changes found on restaging CT scans after treatment with BEP chemotherapy in 
patients with metastatic testicular cancer, and whether fibrosis markers TGF-β1 and GDF-15 and 






We performed a prospective non-randomized biomarker cohort study for which eligibility 
criteria were: patients between 18 and 50 years of age with metastatic testicular cancer who 
were to be treated with BEP chemotherapy in the University Medical Center Groningen. Primary 
assessments were related to cardiovascular parameters. Exclusion criteria were a medical history 
of cardiovascular disease or a creatinine clearance < 60 mL/min. An additional analysis was 
performed on pulmonary parameters. Criteria for this analysis were a minimum of at least two 
bleomycin administrations (60 USP) and presence of a chest CT scan as part of the restaging 
investigations after chemotherapy. Patients were treated with a standard regimen of 3 or 4 
three weekly BEP chemotherapy courses, depending on International Germ Cell Consensus 
Classification (IGCCC) prognosis group. During the first six days of each course, patients received 
daily anti-emetic therapy (dexamethasone and ondansetron). The local ethics committee 
approved the study. All patients gave written informed consent. 
Ct scans 
Post chemotherapy restaging CT scans were analyzed for abnormalities suspect for bleo-
mycin-induced pulmonary changes as judged by two independent radiologists who were 
blinded for clinical phenotype. Patients were instructed to inhale during CT scans of the thorax. 
CT scanning was started 30 seconds after intravenous contrast injection (55 cc Lomeron 350). 
Scans were made in caudalcranial direction from the deepest costophrenic pleural recesses to 
above the thorax aperture. For reconstruction the following parameters were used: 3/1.5 mm on 
Sensation-16 and Symbia T16 and 2/1.5 mm on S-64, Definition and mCT (Kernel B40f ). 
Radiologic criteria for abnormalities on restaging CT scan that were regarded as bleomycin-
induced were that these abnormalities were newly developed since start of BEP chemo-
therapy and could not readily be explained by other factors such as metastases or infection. 
When available, the next CT scan (follow-up scan), made as part of the routine follow-up after 
completion of treatment was assessed to judge whether abnormalities on the restaging CT 
scan, suspected to be the result of bleomycin-induced pulmonary changes, diminished or 
resolved. The type of abnormality was described and abnormalities were scored to be unifocal 
or multifocal with the location and number of lobes involved noted. Extension of radiographic 
abnormalities were graded as minor (only outer third of the lung involved), moderate (outer 
and middle third of the lung involved, but not extending across to the mediastinum) or severe 
abnormalities (whole width of the lung from periphery to mediastinum involved) according to 
Bellamy et al [11]. 
Measurement of biomarkers
EDTA plasma samples were collected for all biomarkers before start of chemotherapy (day 
1), for TGF-β1 on day 1 of every subsequent chemotherapy course, for GDF-15 and hs-CRP at 
day 8 of the third course and for all measured biomarkers at follow-up 4 weeks after the end 
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of chemotherapy. EDTA blood samples were centrifuged at 3000 g at 4°C for 10 minutes and 
plasma was stored at minus 20°C. In these samples total TGF-β1 levels were analyzed after 
activation with hydrochloric acid using a human TGF-β1 Quantikine ELISA-kit (R&D systems 
Abingdon, United Kingdom). GDF-15 levels were measured with the Human GDF-15 Quantikine 
ELISA-kit (R&D systems). Hs-CRP levels were analyzed using the nephelometer. 
statistics 
Differences in biomarker levels were investigated between patients with and without 
pulmonary changes on CT scan and in patients with and without clinical BIP. We also analyzed 
differences between the groups based on amount of changes on CT scan (no, minor, moderate 
or severe abnormalities). Biomarker levels were evaluated as absolute values, relative values 
(normalized to pre-chemotherapy levels) and absolute increases. Mann Whitney U tests and 
Kruskal Wallis tests were used to evaluate differences in biomarker levels between groups. Chi 
square and Fisher exact tests were used to analyze categorical data. A Spearman correlation 
test was used to test correlations. P-values ≤0.05 were considered significant. Statistics were 
calculated with IBM SPSS statistics 22. Graphs were made using GraphPad Prism version 5.00.
results 
Patients
Between May 2006 and June 2012, 78 patients were included in the biomarker study. Two 
patients withdrew consent during the study. In total, five patients were excluded from analysis 
because data were incomplete due to missed measurements. Five patients received ≤ 2 
BEP-courses. Data of 66 patients was analyzed (Figure 1, Table 1). Five of these 66 patients did 
not receive all initially planned bleomycin administrations because of clinical signs of BIP (n = 
3), development of bleomycin skin toxicity (n = 1) and development of a pulmonary embolism 
(n = 1). 




Table 1: Patient characteristics.
  Median (range) Number (%)
Total number of patients 66
























Figure 2. Representative examples of minor graded (upper panel) and moderate graded (lower panel) bleo-
mycin-induced pulmonary changes; pretreatment, restaging and follow-up CT scan (left to right). 
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Bleomycin-induced pulmonary changes on Ct scan
Pretreatment staging CT scans from chest and abdomen were made median 22 (range 1 
- 78) days before start of chemotherapy. Restaging CT scans were made median 21 (range 5 - 
112) days after the last course of chemotherapy. The first CT scan during follow-up was made 
median 175 (range 70 - 588) days after the restaging CT scan. In 45 out of 66 (68%) analyzed 
patients radiological signs suspect for bleomycin induced pulmonary changes were seen on the 
restaging scan. Of these, 37 were classified to have minor and eight to have moderate abnormal-
ities (Figure 2). None were qualified as severe abnormalities. Most abnormalities were multifocal 
and found in the basal parts of the lungs.
There was no relation between the cumulative dose of bleomycin and development of lesions 
suspect for bleomycin toxicity on restaging CT scan. Renal function and smoking frequency were 
not different between groups (Table 2). On available follow-up scans of patients with suspected 
bleomycin-induced pulmonary changes (38/45; 84%), these changes diminished in 14 patients 
and disappeared in 24 patients. No differences were found in patient characteristics between 
these two groups (Table 3). 
In three patients with clinical signs of BIP for which administration of bleomycin was halted, 
the restaging CT scan showed moderate, minor and no abnormalities respectively. 
Biomarker plasma levels 
Table 4 shows biomarker plasma levels of all patients at clinical relevant time points. Median 
plasma levels before start of chemotherapy were 4788 (range 550 - 24369) pg/mL for TGF-β1, 
392 (range 187 - 1935) pg/mL for GDF-15 and 1.3 (range 0.2 - 50.4) mg/L for hs-CRP. No correla-
tion was found between TGF-β1, GDF-15, hs-CRP and tumor marker levels (AFP, β-HCG and LDH) 
before start of treatment in patients with elevated tumor markers (data not shown). 
No significant differences in absolute or relative levels of TGF-β1, GDF-15 and hs-CRP at the 
measured time points were found between patients with no, minor or moderate radiological 
signs of pulmonary bleomycin toxicity. In addition, there were also no significant differences 
found in patients with no or minor versus moderate pulmonary bleomycin toxicity (Table 
4). However, patients who developed pulmonary abnormalities on CT scan (either minor or 
moderate) more frequently had an TGF-β1 increase between day one of the first course BEP 
(before start of chemotherapy) and day one of the second course (86 vs. 60%, p=0.047). Also, 
GDF-15 levels at the 8th day of the third course were higher in patients with moderate changes 
on CT scan than in patients with no or minor changes on CT scan, although this difference was 
not statistically significant (7246 pg/mL vs. 5222 pg/mL, p=0.087). All groups showed the same 
pattern of hs-CRP decrease during chemotherapy and an increase afterwards. Patients with 
clinical signs of BIP had no different biomarker levels compared to other patients (Figure 3). In 
patients with pulmonary abnormalities on follow-up scans that diminished but not disappeared 
(n=14) TGF-β1, GDF-15 and hs-CRP levels were not different compared to the patient group in 
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In this study, all restaging CT scans of patients with disseminated testicular cancer treated 
with BEP chemotherapy for signs of bleomycin-induced pulmonary toxicity were evaluated. In 
68% of these patients radiological abnormalities on the restaging CT scan interpreted as signs 
of bleomycin-induced pulmonary changes were observed. Clinical presentation suspect for BIP 
during treatment, which led to premature termination of bleomycin administration, was seen 
in only 5% of patients. This discrepancy between clinical presentation of BIP and radiological 
signs of bleomycin-induced toxicity on CT scans is striking. Earlier studies reported a much 
higher incidence of abnormalities on restaging CT scans as well, compared to the 10% of the 
patients who classically develop clinical signs of bleomycin-induced pulmonary toxicity [11-13]. 
However, these radiological abnormalities are not very well documented and not reported in 
more recent reports of clinical trials in which bleomycin is a component of the combination 
regimen for metastatic testicular cancer [23]. No high-resolution CT scans were made in any of 
the patients precluding statements on the presence of interstitial pneumonitis.  
The clinical relevance of radiological signs of bleomycin-induced pulmonary abnormalities 
on restaging CT scans remains unclear. Most of these abnormalities on CT scans were without 
accompanying symptoms and resolved spontaneously based on subsequent CT scans several 
months later during follow-up. We questioned whether post treatment radiological findings 
were accompanied by biochemical signs of active fibrosis and whether these could be used as 
early markers of the toxic effect of bleomycin on the lung. 
TGF-β1 is a cytokine involved in many processes in the body and plays a pivotal role in the 
development of lung fibrosis [24]. Various preclinical studies showed a critical role for TGF-β1 in 
the BIP development. In the current study, we did not find a difference in TGF-β1 levels between 
patients with and without radiological signs of bleomycin-induced pulmonary changes. 
However, patients who developed bleomycin-induced pulmonary changes on CT scan more 
often showed an increase of TGF-β1 levels from pre chemotherapy to day one of the second 
course. This may indicate involvement of the TGF-β1 pathway in development of pulmonary 
abnormalities due to bleomycin administration. 
The TGF-β1 plasma levels found in our patients at baseline had a broad range. Plasma TGF-β1 
levels in healthy volunteers also show a threefold difference with a broad range in other studies 
[25,26]. Measured TGF-β1 levels in our patient group may also be tumor derived rather than 
selectively the result of bleomycin-induced pulmonary changes [27]. However, no correlation 
between known tumor markers in testicular cancer and TGF-β1 levels before treatment was 
found. An interesting approach to circumvent this would be to assess TGF-β1 levels during bron-
choalveolar lavage (BAL) to assess only lung TGF-β1 levels [28]. We collected no platelet poor 
plasma, while TFG-β1 might have been released from platelets during collection and analyses of 
the samples [29]. This is a limitation of our study, but does not preclude comparison of TGF-β1 
levels within our patient group. 
We did not find differences in GDF-15 levels in patients with versus patients without bleo-
mycin-induced pulmonary changes on CT scan. Although the increase of GDF-15 levels seemed 
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to be larger in patients with moderate pulmonary changes on CT scans, this was not significant. 
The number of patients with moderate changes (n = 8) might have been too small to detect 
significant differences. In addition, GDF-15 is also known as apoptosis marker [22]. Therefore, 
its distinctive value during cancer therapy is probably limited. Nevertheless, it could be worth 
examining GDF-15 levels in a larger patient group with a moderate degree of pulmonary 
changes on CT scans after BEP chemotherapy. 
Hs-CRP could be an easily accessible biomarker for subclinical inflammation, but levels 
did not differ in patients with compared to patients without bleomycin-induced pulmonary 
changes. This concurred with steroid administration as anti-emetic drugs during chemotherapy. 
Therefore, hs-CRP is probably not an usable biomarker for bleomycin-induced pulmonary 
changes during chemotherapy. 
In conclusion, pulmonary radiological abnormalities suspect for bleomycin induced changes 
are very common on restaging CT scans after BEP chemotherapy for metastatic testicular cancer, 
occurring in two third (68%) of the patients. Most of these radiological abnormalities appear 
to resolve on follow-up CT scans. TGF-β1, GDF-15 and hs-CRP plasma levels before and during 
treatment were not significantly different between patients with and without radiological signs 
of pulmonary bleomycin-induced toxicity and therefore do not seem helpful as early predictive 
biomarkers.  
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In recent years, great progress has been made in the development of targeted therapy against 
cancer. However, it is also more recognized that these treatments are often only successful 
in a subgroup of patients. One of the current challenges in oncology lies in identifying these 
patients and thereby avoiding treating patients with non-effective treatments and thus avoid 
side-effects of these drugs and reduce costs. Another challenge in oncology is to minimize the 
side effects of currently used therapies. Patients are at risk for developing (long term) and even 
deadly side effects of anticancer treatments and might need adjustments to their treatment 
schedule and specific follow up long after the end of treatment to timely recognize and address 
these. 
One of the targeted therapies that made its way into clinical research in recent years is the 
induction of apoptosis by agonistic antibodies or rhTRAIL via the extrinsic pathway. In preclin-
ical studies, these drugs have been shown to induce apoptosis as monotherapy and enhance 
the effectiveness of chemotherapy and radiotherapy. In chapter 2, we reviewed the phase 1 and 
phase 2 (combination) studies that have been performed with these drugs. Although rhTRAIL 
and the diverse agonistic antibodies against TRAIL-R1 and TRAIL-R2 all seem safe with only one 
maximum tolerated dose found for lexatumumab (elevations of serum amylase, bilirubin and 
transaminases), the effectiveness of these drugs both as monotherapy and in combination with 
chemotherapy is disappointing. However, we also describe novel approaches with TRAIL linked 
to a tumor specific antibody that might lead to better results in the clinic. Also, the combination 
of mapatumumab with chemotherapy and radiotherapy was investigated in a phase 1/2 study 
(NCT01088347). Results of this study are awaited. 
When the targeted drug imatinib entered the clinic in early clinical studies in patients with 
GIST it was noticed that within one to several days a remarkable change in FDG uptake in the 
tumors occurred. It was suggested that this change in uptake could serve as a predictive marker 
for the efficacy of this therapy. Several small studies with FDG-PET in this setting have been 
conducted since, leading to variable results. However, it has become clear that the majority of 
patients (85%) have clinical benefit from this treatment. A predictive test that identifies patients 
that have clinical benefit would therefore not be that informative, but a test that identifies 
patients that will not respond (primary resistance) is. In chapter 3 we retrospectively assessed 
the usefulness of FDG-PET scans made before start of imatinib and 1 week after start of imatinib 
for identification of non responders. Two out of 29 patients showed progressive disease on CT 
scan after 8 weeks as defined by the RECIST criteria. These patients also showed a response 
(defined as at least 25% decrease in standard uptake value (SUV)) on the FDG-PET scan. On the 
other hand the three patients who did not show a response on the FDG-PET scan all did have 
clinical benefit of imatinib. We therefore concluded that performing a FDG-PET scan is not useful 
in identifying patients with primary resistance against imatinib and that the early responses 
seen on FDG-PET scan might be caused by a change in glucose metabolism that is independent 
of the tumor response. 
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In glioblastomas the Macdonalds criteria are used for response assessment and the tumor 
is measured as the contrast enhancing area found on gadolinium enhanced MRI. Response 
assessment during and after treatment is hampered by the phenomenon of pseudoprogres-
sion: the MRI performed directly after completion of chemoradiotherapy shows increased 
contrast enhancement compared to the baseline MRI, but this enhancement remains stable or 
subsides on follow up scans without change of therapy. In chapter 4 we reported on a study 
that prospectively assessed FLT-PET scans made before start of treatment (after initial surgery) 
and 4 weeks after completion of chemoradiotherapy. 18F-FLT is a PET tracer that is taken up 
by proliferating cells and therefore it might potentially be of interest to use FLT-PET scans to 
discriminate between true tumor growth and pseudoprogression. In 24 evaluable patients, 
seven patients showed true progression and seven showed pseudoprogression on MRI. We 
observed no difference in (change in) FLT uptake between patients classified as true progression 
and patients classified as pseudoprogression. Therefore  FLT-PET scan in this setting cannot be 
used to discriminate between true disease progression and pseudoprogression in glioblastoma 
patients treated with chemoradiotherapy. 
In high grade gliomas successful targeted drugs are also eagerly awaited, as there is currently 
no standard therapy for recurrent disease and the median overall survival for the most common 
subtype (glioblastoma) is only 14 months. Numerous targeted agents have been investigated in 
recent years, but so far no therapy has improved the overall survival. A key question in systemic 
treatment of high grade gliomas is if the agents can reach the tumor because of the blood brain 
barrier. In chapter 5 we reported on a study in which a monoclonal antibody against TGF-β 
(fresolimumab) was labeled with Zirkonium-89. After the 89Zr-fresolimumab PET scan, patients 
were treated with intravenously administered fresolimumab. The goal of this study was to 
show that the antibody could reach the tumor and to quantify the uptake and correlate this 
uptake with the outcome of treatment with fresolimumab. In all 12 patients we saw uptake of 
89Zr-fresolimumab in tumor lesions, although not in all individual lesions. Of the lesions that 
were > 1 cm and not visible on the PET scan, 2 out of 3 were previously irradiated and might 
therefore not represent active tumor tissue with TGF-β signaling. We also found that over time 
the tumor to blood ratio increased in four patients who underwent a PET scan on both day 2 
and day 4 after the tracer injection. These findings suggest that the uptake of 89Zr-fresolimumab 
in the tumor is specific rather than just a perfusion related phenomenon. Treatment with 
fresolimumab was well tolerated by all patients, but it did not seem to be beneficial in terms 
of inducing tumor response as second line treatment. However, we did show that a labeled 
antibody is able to reach high grade gliomas. 
TGF-β is important in many processes in both health and disease. From preclinical research, 
we know that TGF-β plays an important role in the development of bleomycin induced 
pulmonary toxicity. This toxicity is a problem in testicular cancer patients that are treated with 
bleomycin containing chemotherapy regimens. This treatment has a very high cure rate, but 
in up to 10% of the patients bleomycin induced pulmonary toxicity occurs, which is fatal in 




suspect for bleomycin-induced pulmonary changes on restaging CT scans after treatment, 
and whether the fibrosis markers TGF-β1 and Growth Differentiation Factor -15 (GDF-15), and 
hs-CRP were predictive of this. We found signs of bleomycin-induced pulmonary changes on 
the restaging CT scan in 68% of the patients. Plasma levels of TGF-β1, GDF15 and Hs-CRP were 
not predictive for the occurrence and severity of CT alterations suspect for bleomycin toxicity or 
clinical pulmonary toxicity. We concluded that bleomycin-induced pulmonary changes are very 
common on restaging CT scans after BEP chemotherapy for metastatic testicular cancer, but 
plasma levels of TGF-β1, GDF15 and Hs-CRP cannot be used as biomarkers for this. 
future PersPeCtives
The recent rapid unraveling of tumor characteristics and the use of these insights for the 
application of targeted therapy has led to hope that cancer will become a chronic disease in the 
coming years [1]. In spite of this optimism, it has also become clear that new discoveries and 
developments raise new questions and challenges. 
In metastatic and irresectable GIST tumors, the introduction of the targeted drug imatinib 
spectacularly improved response rates compared to chemotherapy. Unfortunately, many 
targeted drugs that seemed promising in preclinical research did not live up to the expecta-
tions in phase 1 and 2 studies. Agonistic antibodies against TRAIL receptors and rhTRAIL are well 
tolerated and can be combined with chemotherapy. However, none of the randomized phase 
2 studies so far has shown an improvement of progression free survival or overall survival. This 
underlines the enormous challenges in finding drugable targets, identifying patients that will 
benefit from treatment with targeted drugs, the need for rational combination therapies and 
perseverance when clinical results do not directly live up to the expectations found in preclinical 
research. 
In glioblastomas, driver mutations and pathways are still not elucidated and there is no 
targeted agent available that does improve overall survival [2]. Although TGF-β is an important 
tumor promoter in these tumors, treatment with fresolimumab did not result in clinical benefit 
in our small study with pretreated patients. Since many pathways are deregulated in high grade 
gliomas, better results might be expected from combination treatment targeting multiple 
relevant pathways. Since we did show in our study that fresolimumab is able to reach brain 
tumors, other antibody-related drugs such as antibody-drug conjugates are also of potential 
interest for this indication (NCT01475006).
A key requirement in successful anticancer drug development is to establish the molecular 
and genetic characteristics of tumors. Studies in which biopsies are taken before and after 
(investigational) treatment with targeted agents are currently performed and will learn us more 
about tumor characteristics, patient selection and development of resistance mechanisms 
against targeted agents. In the future, this will lead to more personalized medicine, in which a 
patient receives a treatment based on the specific characteristics of the tumor.
However, it is also known that primary tumor lesions and metastatic lesions can have 
different characteristics and tumor characteristics can change over time [3]. Taking multiple 
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biopsies at different time points to characterize the heterogeneity will often not be feasible 
due to patient inconvenience and tumor lesions that cannot be approached safely. Molecular 
imaging is a more patient friendly approach to assess the characteristics of all different tumor 
lesions. Diverse studies show promising results with this approach [4,5]. However, we showed 
that the initial optimism about the use of FDG-PET to predict responses of imatinib in GIST has 
been premature. Furthermore, response criteria for PET imaging still need to be established and 
might be different for different PET tracers. More and larger studies establishing this and studies 
directly comparing PET results with pathology results are therefore urgently needed and are 
currently performed (NCT01957332). 
Since the introduction of targeted agents in the clinic it has also become clear that the current 
response assessment with CT scans may be suboptimal because targeted agents do not always 
induce a volume response. Initiatives to define new criteria in which also PET responses might 
be included are under investigation [6]. In brain tumors the Macdonalds criteria have already 
been replaced by the RANO criteria, in order decrease the number of pseudoprogression and 
pseudoresponses found [7]. However, for this indication also a combination of conventional 
imaging and molecular imaging will be needed to accurately assess responses of current and 
future therapies. We showed that serial FLT-PET scan was not helpful in discriminating pseudo-
progression from true progression in primary glioblastoma patients treated with chemoradio-
therapy. However, approaches using other parameters such as kinetic analysis may overcome 
the difficulty of discriminating between tracer uptake and leakage due to a disrupted blood 
brain barrier. Also other imaging modalities such as perfusion MRI and 11C-methionine-PET 
show promising results and are currently under more detailed investigation [8,9]. 
An interesting development in imaging that circumvents the irradiation burden of PET scans 
is optical imaging. Its use is currently limited by the tissue penetration of the optical tracers 
which makes whole body scanning impossible, but it is especially investigated for surgical appli-
cations. Since optimal surgical resection is one of the predictive markers for overall survival in 
glioblastoma, tumor resection using optical imaging with a specific tracer might be a promising 
tool to discriminate infiltrating tumor from normal brain tissue [10,11]. 
With the increasing number of cancer patients and improvements in treatment, the number 
of cancer survivors is also increasing [12]. Long term effects of anticancer treatments are 
therefore gaining more attention. We know that particular attention needs to be paid to cardio-
vascular diseases and secondary malignancies in long term cancer survivors [13]. Biomarkers 
may help to identify patients at risk for long term and harmful side effects. A challenge for the 
future will be to prevent predicted (long term) toxicity without jeopardizing the efficacy of 
anticancer treatments resulting in a balanced trade-off. 
In conclusion, notwithstanding the enormous challenges ahead, cancer medicine will 
become more and more personalized: new imaging techniques will be able to reveal tumor 
characteristics, specific drugs will be able target these, specific patients characteristics will be 
taken into account and the follow up of patients will be aimed at the specific long term effects 
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Er is in de afgelopen jaren veel vooruitgang geboekt in de ontwikkeling van ‘doelgerichte 
behandelingen’ tegen kanker. Helaas wordt ook steeds duidelijker dat deze behandelingen vaak 
alleen succesvol zijn in een subgroep van de patiënten. Eén van de belangrijkste uitdagingen 
in de oncologie op dit moment is het identificeren van deze patiënten, zodat kan worden 
voorkomen dat patiënten onnodig behandeld worden met voor die patiënt niet werkzame 
therapieën. Dit voorkomt bij patiënten onnodige bijwerkingen en bespaart kosten. Een andere 
uitdaging in de oncologie is het minimaliseren van bijwerkingen van huidige behandelingen. 
Antikankerbehandelingen kunnen ernstige en zelfs dodelijke (lange termijn) bijwerkingen 
hebben. Aanpassing van het behandelschema en specifieke follow up kunnen nodig zijn om 
bijwerkingen tijdig te herkennen, te behandelen en voorkomen. 
Eén van de doelgerichte antikanker behandelingen die in de afgelopen jaren onderzocht 
is, is het induceren van apoptose door agonistische antilichamen of rhTRAIL via de extrinsieke 
route. In preklinische studies is aangetoond dat deze middelen zowel als monotherapie 
apoptose kunnen veroorzaken, als de effectiviteit van chemotherapie en radiotherapie kunnen 
verbeteren. In hoofdstuk 2 hebben we de fase 1 en fase 2 (combinatie) studies die tot dusverre 
met deze middelen zijn uitgevoerd geanalyseerd. rhTRAIL en de verschillende agonistische anti-
lichamen tegen TRAIL-R1 en TRAIL-R2 lijken veilig te zijn. Alleen voor lexatumumab werd een 
maximale tolereerbare dosering gevonden. Helaas valt de effectiviteit van deze middelen zowel 
als monotherapie als in combinatie met chemotherapie en andere doelgerichte medicatie tegen. 
Nieuwe benaderingen waarbij TRAIL wordt gekoppeld aan een tumor specifiek antilichaam 
kunnen mogelijk tot betere resultaten leiden. Daarnaast is de combinatie van mapatumumab 
met chemotherapie en radiotherapie onderzocht in een fase 1/2  studie (NCT01088347). 
Toen het medicijn imatinib, een c-Kit-tyrosinekinaseremmer, voor het eerst werd toegepast 
bij patiënten met een GIST, viel het op dat binnen enkele dagen een verandering zichtbaar 
was in de hoeveelheid FDG die werd opgenomen door de tumoren. Mogelijk kon deze 
verandering in opname worden gebruikt als een predictieve marker voor de effectiviteit van 
de behandeling. Er zijn sindsdien verschillende kleine studies met FDG-PET gedaan in deze 
setting, met wisselende resultaten. Inmiddels is echter ook duidelijk geworden dat het grootste 
deel van de patiënten (85%) baat heeft bij behandeling met imatinib. Een predictieve test die 
patiënten identificeert die baat hebben bij de behandeling is daarom niet zo interessant, maar 
een test die patiënten identificeert die niet reageren op dit middel en zo primaire resistentie 
aantoont, wel. In hoofdstuk 3 beschreven we een retrospectieve studie waarin de bruikbaar-
heid van FDG-PET scans voor het identificeren van patiënten die niet op imatinib reageren is 
geanalyseerd. Deze FDG-PET scans werden gemaakt voor start van imatinib en 1 week na start 
van imatinib. Twee van de 29 patiënten hadden progressieve ziekte op de CT scan na 8 weken 
volgens de tumor respons RECIST criteria. Deze twee patiënten hadden echter ook een respons 
(gedefinieerd als tenminste 25% afname in ‘standard uptake value’ (SUV)) op de FDG-PET scans. 
Aan de andere kant hadden drie patiënten die geen respons hadden op de FDG-PET scans wel 
baat bij imatinib. We hebben daarom geconcludeerd dat een FDG-PET-scan niet bruikbaar is 
117
Nederlandse samenvatting | 
voor het identificeren van patiënten met primaire resistentie tegen imatinib en dat de vroege 
veranderingen op FDG-PET scan mogelijk veroorzaakt worden door veranderingen in het gluco-
semetabolisme die niet direct verband houden met een tumorrespons. 
In glioblastomen worden de Macdonalds criteria, waarbij het gebied met gadolinium 
contrast opname op MRI wordt gemeten, gebruikt voor tumorrespons evaluatie. Deze evaluatie 
wordt echter bemoeilijkt door het fenomeen pseudoprogressie; op de MRI direct na chemo-
radiotherapie is een toegenomen gebied met contrast opname zichtbaar, maar dit gebied 
blijft stabiel of neemt af op volgende MRI scans zonder verandering in de behandeling. In 
hoofdstuk 4 beschreven we een studie waarbij we prospectief keken naar FLT-PET scans 
gemaakt voorafgaand aan (na primaire chirurgie) en 4 weken na chemoradiotherapie. 18F-FLT is 
een PET tracer die wordt opgenomen door prolifererende cellen en de FLT-PET scan kan daarom 
mogelijk gebruikt worden om onderscheid te maken tussen echte tumorgroei en pseudopro-
gressie. Van de 24 evalueerbare patiënten hadden er zeven echte progressie en zeven pseudo-
progressie. We vonden geen verschil in (verandering van) FLT-opname tussen patiënten met 
pseudoprogressie en echte progressie. De FLT-PET scan heeft geen directe waarde in het maken 
van dit onderscheid in deze patiëntengroep. 
Voor hooggradige gliomen wordt ook hard gezocht naar succesvolle doelgerichte 
behandeling. Er is dit moment geen standaardtherapie voor recidief tumoren. De mediane 
totale overleving voor het meest voorkomende subtype (glioblastoom) is slechts 14 maanden. 
In de afgelopen jaren zijn verschillende doelgerichte behandelingen onderzocht, maar tot nu 
toe heeft geen enkele behandeling de totale overleving verbeterd. Een essentiële vraag bij 
de systemische behandeling van hooggradige gliomen is of de medicatie de tumor wel kan 
bereiken vanwege de bloedhersenbarrière. In hoofdstuk 5 beschreven we een studie waarin 
een monoklonaal antilichaam tegen TGF-β (fresolimumab) gelabeld werd met Zirkonium-89. 
Na het ondergaan van 89Zr-fresolimumab PET scans werden patiënten behandeld met fresoli-
mumab. Het doel van deze studie was om aan te tonen dat het antilichaam de hersentumor 
kon bereiken, de opname van deze tracer in de tumor te kwantificeren en deze opname te 
correleren aan de uitkomst van de behandeling. In alle 12 patiënten zagen we opname van 
89Zr-fresolimumab in tumorlaesies. Echter, niet in alle individuele laesies werd opname gezien. 
Van de 3 laesies die groter waren dan 1 cm en niet zichtbaar op de PET scan, waren er 2 eerder 
bestraald en doordoor mogelijk radionecrose in plaats van actief tumorweefsel, waardoor er 
geen 89Zr-fresolimumab opname zichtbaar was. We zagen ook dat de tumor-bloedratio toe nam 
in de vier patiënten die een PET scan hadden ondergaan op zowel dag 2 en dag 4 na trace-
rinjectie. Deze bevindingen suggereren dat de tumoropname van 89Zr-fresolimumab specifiek 
is en niet een aan perfusie gerelateerd fenomeen. Behandeling met fresolimumab werd goed 
verdragen door patiënten, maar het induceerde geen tumorresponsen. We hebben met deze 
studie echter wel aangetoond dat een gelabeled antilichaam in staat is om hooggradige 
gliomen te bereiken.   
TGF-β is belangrijk voor diverse fysiologische en pathologische processen in het lichaam. Uit 




bleomycine geïnduceerde longtoxiciteit. Deze toxiciteit vormt een probleem voor patiënten met 
testiskanker die worden behandeld met chemotherapie waarvan bleomycine een onderdeel is. 
Deze behandeling is heel vaak curatief, maar in ongeveer 10% van de patiënten ontstaat long-
toxiteit door bleomycine, die in 10% van de gevallen fataal is. In hoofdstuk 6 hebben we de 
spiegel van TGF-β1, GDF-15 en Hs-CRP in het plasma van testiskankerpatiënten voor, tijdens 
en na behandeling met bleomycine geanalyseerd. We analyseerden ook de prevalentie van 
afwijkingen die verdacht waren voor door bleomycine geïnduceerde longtoxiciteit op de resta-
geringsscans. We vonden radiologische veranderingen verdacht voor toxiciteit van bleomycine 
bij  68% van de patiënten. De hoeveelheid TGF-β1, GDF-15 en Hs-CRP in het plasma was niet 
voorspellend voor het ontstaan en de ernst van de radiologische veranderingen verdacht 
voor toxiciteit van bleomycine of voor klinische tekenen van longtoxiciteit. We concludeerden 
daarom radiologische veranderingen verdacht voor toxiciteit van bleomycine veel voorkomen, 
maar dat de onderzochte markers niet als biomarkers voor het ontstaan hiervan kunnen worden 
gebruikt. 
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